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Abstract 
 
The SRY (sex-determining region Y) - box 2 (SOX2) is a master factor 
in the maintenance of pluripotency and stemness. The transcription 
factor SOX2 allows the cells to maintain the unique characteristics of 
the embryonic stem cells (ESCs), such as clonogenicity, pluripotency, 
self-renewal ability, and conservation of the anti-apoptotic properties 
of cancer stem cells (CSCs). This factor has an important role in 
carcinogenesis of several tumors, including gastric, breast, pancreatic, 
and lung cancers. SOX2 overexpression can contribute to resistance 
of cancer cell to drug therapy and has been associated with tumor 
aggressiveness and worse prognosis. Ras GTPase is a proto-oncogene 
activated in several types of cancer with low success rate, including 
carcinomas of the pancreas, colon, lung, thyroid, and myeloid 
malignancies. This oncogene activates several signalling pathways, 
which includes the MAPK, PI3K, and RAL. It’s signalling is involved in 
many cellular functions, such as cell proliferation, apoptosis, 
migration, fate specification, and differentiation. This project aims to 
investigate the role of SOX2 on RasV12-mediated transformation and 
the genetic requirements for SOX2 induction mediated by Ras using 
immortalized mouse fibroblasts and primary mouse embryonic 
fibroblasts. We also study the effect of SOX2 overexpression on drug 
therapy using human lung carcinoma and human breast 
adenocarcinoma cell lines. We have demonstrated that RasV12 
overexpression induced the expression of SOX2 and this induction is 
at level of transcription.  We also determined that p53, Rb, and p19ARF 
factors are not essential for SOX2 induction and that MAPK pathway 
is required, but not sufficient for SOX2 induction by RasV12. Through 
a transformation assay we demonstrate that SOX2 overexpression 
increases the effect of RasV12 in cell transformation and SOX2 
silencing mediated by siRNA decreases the transformation capacities 
of RasV12, so this factor is important in transformation mediated by 
 
 
RasV12. Several studies show that SOX2 not only influences tumor 
growth, but it also influences the response of tumor cells to 
therapeutic drugs. We observed that SOX2 overexpression increased 
the resistance of human breast adenocarcinoma cells to docetaxel. In 
conclusion, SOX2 is a key factor in cell transformation mediated by 
RasV12, as well as has an important role in chemoresistance of cancer 
cells. Looking at these results, this factor can be a novel target for anti-
cancer therapy. 
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Cultura de células, SOX2, RasV12, transformação oncogénica, 
quimiorresistência  
Resumo 
 
O fator de transcrição SOX2 (Sex-determining region Y (SRY)-Box2) é 
um fator importante na manutenção da pluripotência e “stemness”. 
Este fator permite que as células preservem as características únicas 
das células embrionárias estaminais (ESCs), como a clonogenicidade, 
pluripotência, capacidade de autorrenovação e a conservação das 
propriedades anti-apoptóticas de células estaminais cancerígenas 
(CSCs). O SOX2 tem um papel importante na carcinogénese de vários 
tumores, como no cancro gástrico, da mama, pancreático e do 
pulmão. A sobre-expressão de SOX2 pode contribuir para a 
resistência das células cancerígenas à terapia farmacológica e tem 
sido associada à agressividade tumoral e mau prognóstico. O proto-
oncogene Ras GTPase está ativo em vários cancros com baixa taxa de 
sucesso, como os carcinomas do pâncreas, colón, pulmão, tiroide e 
mielomas malignos. Este oncogene ativa múltiplas vias de sinalização, 
incluindo a MAPK, PI3K e RAL e estas vias estão envolvidas em funções 
celulares como proliferação celular, apoptose, migração e 
diferenciação. Este projeto tem como objetivo investigar o papel de 
SOX2 na transformação mediada por RasV12 e os fatores genéticos 
importantes na indução de SOX2 usando fibroblastos imortalizados 
de rato e fibroblastos embrionários primários de rato e o efeito da 
sobre-expressão de SOX2 na terapia farmacológica usando células do 
carcinoma do pulmão humano e células do adenocarcinoma da mama 
humano. Foi possível demostrar que a sobre-expressão de RasV12 
induz a expressão de SOX2 ao nível da transcrição. Os fatores p53, Rb 
e p19ARF não são essenciais na indução de SOX2 por RasV12, no 
entanto a via de sinalização MAPK é necessária neste processo. 
Através de ensaios de transformação foi possível demonstrar que a 
sobre-expressão de SOX2 incrementa o efeito de RasV12 na 
transformação celular e que o silenciamento de SOX2 usando siRNA 
diminui a capacidade transformante de RasV12, desta forma este 
fator é importante para a transformação celular mediada por RasV12. 
 
 
Vários estudos demonstram que o fator de transcrição SOX2 não só 
influencia o desenvolvimento tumoral, mas também a resposta das 
células tumorais à terapia farmacológica. Foi possível verificar que a 
sobre-expressão de SOX2 aumenta a resistência de células do 
adenocarcinoma da mama humano ao agente farmacológico 
docetaxel. Em conclusão, SOX2 é um fator essencial na transformação 
celular mediada por RasV12, assim como tem um papel importante 
na resistência das células cancerígenas à terapia. Olhando para estes 
resultados, este fator pode ser o novo alvo terapêutico na luta contra 
o cancro. 
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Introduction 
 
1. Cancer 
Cancer is known as a disease responsible for uncontrolled growth and spread of abnormal 
cells. In 2013 1 660 290 new cancer cases were diagnosed, in which about 174 100 cancer deaths 
were caused by tobacco use. Currently, several forms of cancer can be treated and in 2013 
approximated 13.7 million people with cancer history were alive (Asati et al., 2016b). 
Carcinogenesis is an event that transforms differentiated tissues into an immature cell 
population. The progression of this neoplasia in cancer cells lead to accumulation of genetic and 
epigenetic modifications, by multiple DNA mutations and clonal selection (Atoraih et al., 2016). 
Therefore, cancer is a disease associated with genomic instability that results, frequently, from 
oncogene activation (Kotsantis et al., 2016). These alterations make cancer cells return to 
immature undifferentiated phenotype and acquire novel molecular signatures. Tumor cells 
share several biological characteristics with normal stem/progenitor cells (Chou et al., 2013), for 
this the activation of transcription factors of stem cells is an important event in the development 
of cancer (Atoraih et al., 2016), and the malignant process of the cell involves abnormal cell 
growth, proliferation, and differentiation (Asati et al., 2016a). 
Hanahan and Weinberg suggest that almost all types of human cancers acquired ten 
capabilities during their development. These hallmarks of cancer are: sustaining proliferative 
signalling, evading growth suppressors, avoiding immune destruction, enabling replicative 
immortality, tumor promoting inflammation, activating invasion and metastasis, inducing 
angiogenesis, genome instability and mutation, resisting cell death and deregulation cellular 
energetic. The development of this multiple hallmarks depends in large part on a succession of 
changes in the genomes of neoplastic cells (Hanahan and Weinberg, 2011).  
The acquisition of gene mutations on driver oncogenes and/or tumor suppressors is one of 
the main causes of tumor initiation and maintenance, and the cancer cell survival depends on a 
few oncogenes that sustain the malignancy (Jung et al., 2016).  
Replication stress that occur when DNA replication fork progression in S phase slows or 
stalls is a mechanism proposed to cause genomic instability in cancer. This cause the collapse of 
forks into DNA double-strand breaks (DSBs) and incomplete sister chromatid separation in the 
following mitosis. Marks of spontaneous replication stress are found in cancer samples and cells 
expressing active oncogenes, and replication stress promotes chromosomal instability (Kotsantis 
et al., 2016). 
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The overexpression of oncogenes, such as Ras or Myc is sufficient to induce replication 
stress in culture cells and these oncogenes promoting cell growth and division by acting in the 
growth factor signalling pathways that stimulate proliferation (Kotsantis et al., 2016).  
Several evidences suggest that the genetic and epigenetic alterations of protein-coding 
genes cannot constitute the entire molecular basis fundamental for the pathogenesis of tumor 
development. The majority of non-coding RNA (ncRNA) that influence tumorigenesis act to 
regulate gene expression through a diverse range of molecular mechanisms, and the 
retrotransposons seems to have a potential role in promoting tumorigenesis (Xue and He, 2014). 
The long non-coding RNAs (lncRNAs) regulate individual genes and gene expression through 
epigenetic regulation or by altering the basal transcriptional machinery. They have a role in, for 
example, chromosome dosage-compensation, imprinting, epigenetic regulation, cell cycle 
control, nuclear and cytoplasmic trafficking, transcription, translation, splicing, and cell 
differentiation. For that, their abnormal expression is associated with numerous diseases 
including cancer (Jiang et al., 2016). 
In cancer cells, several lncRNAs present alterations in the expression levels when compared 
with healthy tissue of the same origin. Its deregulated are involved in proliferation, apoptosis, 
and cell-cycle control in the tumorigenesis, and also contribute to the specific process of 
metastasis (Jiang et al., 2016). 
Many microRNA (miRNA) have been identified to promote or suppress oncogenesis in 
mouse tumor models, cell culture systems, and clinical studies by regulating essential cellular 
processes during the tumorigenesis. Specific miRNA and components of the miRNA biogenesis 
machinery have genetic and epigenetic alterations in a diversity of human cancers (Xue and He, 
2014). 
The initiation and progression of cancers carrying the oncogenic and tumor suppressor 
mutations that define cancer as a genetic disease (Hanahan and Weinberg, 2011), but the 
molecular mechanisms that regulate tumor initiation and stemness are still poorly characterized 
(Boumahdi et al., 2014). One the other hand, genetic profiling of human malignancies have led 
to a better understanding of cancer biology and a refined molecular classification of cancer types 
(Schröck et al., 2014). 
The regulation of the cell proliferation and apoptotic pathways associated with cell death is 
an important approach to understand about cancer cells. For that, the identification of cell-cycle 
regulates and apoptotic stimuli to combat cancer cells is an attractive approach for the discovery 
and development of potential anti-cancer agents (Asati et al., 2016b).  
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2. The SOX family of transcription factors 
The SOX (SRY-related HMG-box) gene family was first defined by the discovered of the Sry 
gene, sex-determining region of the Y-chromosome, in humans and mice in the 90s associated 
with primary male sex determination and, subsequently, testis development. This gene family 
encodes transcriptional factors with a highly conserved HMG (high-mobility-group) box, which 
is a 79 amino-acid DNA-binding domain (Zhang and Cui, 2014; She and Yang, 2015). Through the 
HMG domain, SOX proteins can bind to ATTGTT or related sequence motifs (Kamachi and 
Kondoh, 2013). 
In vertebrates, SOX family is composed of more than 20 SOX genes which originated 
through a process of duplication and divergence (She and Yang, 2015). This family is 
characterized by three domains: N-terminal, HMG allowing the recognition, and a specific 
binding to DNA and C-terminal  (Marqués-Torrejón et al., 2013; Weina and Utikal, 2014). SOX 
family are expressed in an extensive variety of tissues and have important role in tissue 
homeostasis, regulation of organ development (organogenesis), and cell-type specification in 
many developmental processes from embryonic through to adult stages (Karachaliou et al., 
2013; Li et al., 2015; She and Yang, 2015). 
The family of SOX transcription factors are divided in eight groups (A-H) based upon HMG 
box sequence, protein structures, gene organization, and their function (Thu et al., 2014; She 
and Yang, 2015). Members within a subfamily retain 80% identity in their HMG-domain and 
other conserved regions and might have overlapping expression patterns, share biochemical 
properties, and perform synergistic or redundant function. By contrast, members from different 
subgroups usually develop different functions (Garros-Regulez et al., 2016). 
The SRY protein belongs to group A and play an essential role in sex determination. The 
SOXB group is split into two subgroups, the SOXB1 group proteins composed by SOX1, SOX2, 
and SOX3 factors that share more than 80% sequence similarity and have an important function 
for embryonic development and in the central nervous system as transcriptional activators 
(Marqués-Torrejón et al., 2013; Zhang and Cui, 2014; She and Yang, 2015), and the subgroup 
SOXB2 (SOX14 and SOX21) act as transcription inhibitors. The proteins SOX4, SOX11, and SOX12 
belongs to SOXC group, SOXD group is composed by SOX5, SOX6, and SOX13 proteins, and SOX8, 
SOX9, and SOX10 protein belongs to SOXE group. Lastly, SOXF group is composed by SOX7, 
SOX17, and SOX18 proteins, SOX15 and SOX30 proteins belongs to SOXG and SOXH groups, 
respectively (Kamachi and Kondoh, 2013; She and Yang, 2015). 
SOX proteins exhibit their gene regulatory functions only by the formation of complexes 
with partner transcription factors. A functional SOX-binding site has a binding site for a second 
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partner protein, which required for SOX-dependent transcriptional regulation. The binding of a 
single SOX protein alone to a DNA site does not lead to transcriptional activation or repression. 
In the absence of DNA, SOX proteins are capable of interact with the partner factors, this show 
that the SOX-partner complexes can form first and then recognize target DNA sites as a complex 
(Kamachi and Kondoh, 2013). 
This protein family do not show their activating or repressive regulatory functions when 
they bind to DNA on their own, but instead bind specific DNA sequences in combination with 
partner proteins to exert their effects (Kamachi and Kondoh, 2013). 
During the development, the transcriptional activities of SOX proteins are regulated for 
multiple genetic pathways. The three major aspects of such regulation are: the regulation of the 
expression levels of SOX proteins in specific cell types and tissues and at precise timings within 
a series of major developmental stages, regulation of post-translational modifications of SOX 
proteins, and regulation of recruited partner proteins. In the last case this regulation influence 
the specification recognition of the binding sites of SOX-partner complexes on the target genes 
and determine transcription activities and significantly enhance the activation/repression 
potential (She and Yang, 2015). 
 
 
2.1 SOX2 
SOX2 gene, a member of the SRY gene family (Acanda de la Rocha et al., 2016) is in 
chromosome 3 (3q26.3-q27) of Human genome and encodes for SOX2 protein (Sex-determining 
region Y (SRY)-box (SOX)2) with 317 amino acids (Weina and Utikal, 2014). The SOX2 protein 
belongs to SOX transcription factors (Herreros-Villanueva et al., 2013), more precisely to SOXB1 
group (Zhang and Cui, 2014) and containing three domains: N-terminal, high mobility group 
(HMG) DNA-binding domain, and C-terminal domain  (Figure 1) (Schröck et al., 2014; Weina and 
Utikal, 2014).  
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Figure 1. Homology, structure, and product of SOX2 gene. (A) SOX2 belongs to the SOXB1 group of SOX 
protein. Elements of this group contains three domains: N-terminal, HMG, and C-terminal. (B) The HMG 
domain is highly conserved and serves as potential binding sites for protein partners. Binding of the 
nuclear import signals (NIS) and nuclear export signals (NES) to the HMG domain leads to regulation of 
SOX2 itself. The transactivation domain as the region responsible for promoter binding, which leads to 
activation or repression of target genes (Weina and Utikal, 2014). 
 
The expression of SOX2 is regulated by intrinsic factors and extrinsic signalling pathways. In 
the SOX2 locus there are several regulatory regions (SRR) that are responsible for controlling the 
expression of this gene, which include SOX2 core promoter and a number of enhancers located 
upstream and downstream of the gene (Figure 2). These regulatory regions are very conserved 
across species (Zhang and Cui, 2014).  
 
Figure 2. Transcriptional expression of SOX2 is regulated by multiple enhancers in the locus. SOX2 gene 
locus is represent with SOX2 exon, the location of the N1 to N5 enhancers, the transcription starting (TSS) 
and termination site (TTS), and regulatory regions 1 (SRR1) and 2 (SRR2) (Zhang and Cui, 2014). 
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SOX2 protein is found in the cell nucleus and forms a complex with an Oct4 (Octamer-
binding transcription factor 4) protein in DNA, regulating the gene expression involved in cell 
differentiation during embryonic development (Herreros-Villanueva et al., 2013; Weina and 
Utikal, 2014; Rizzino and Wuebben, 2016). SOX2-Oct4 regulatory complex upregulates a large 
number of genes (Karachaliou et al., 2013), involved in maintenance of stem cells in adult 
tissues, sex determination, and development of central nervous system and hematopoietic cells 
(Thu et al., 2014; Wang et al., 2015).  
SOX2 is one of the four pluripotency factors which include Oct4, Myc, and Klf4 (Krüppel-
like-factor 4), also called Yamanaka factors. The combination of these factors is sufficient to 
reprogram differentiated cells in induced pluripotent stem cells (iPSCs), embryonic-like state 
(Figure 3). SOX2 factor is essential in the last phase of reprogramming process, this is responsible 
for its own transcription as well as others of pluripotency-associated genes to stabilize the 
pluripotent state and finally to generate an iPSC. The endogenous SOX2 locus activation during 
reprogramming process leads to several transcriptional changes in cells intended to form iPSC 
(Chanoumidou et al., 2017). The iPS cells exhibit morphological and growth properties of 
embryonic stem cells (ESCs) and express gene markers of embryonic stem cells (Takahashi and 
Yamanaka, 2006). The two properties more important of the pluripotent stem cells (PSCs) are 
indefinite self-renewal in culture and the ability to generate most, if not all, cell types in the body 
by differentiation into one of the three embryonic germ layers (Zhang and Cui, 2014). 
The transcription factor SOX2 allows the cells, through a complex transcriptional regulation 
network, to maintain the unique characteristics of ESC, such as clonogenicity, pluripotency, self-
renewal ability, and conservation of the anti-apoptotic properties of cancer stem cells (CSCs) 
(Chen et al., 2012; Karachaliou et al., 2013). These characteristics enable the initiation of a tumor 
to maintain its growths and recurrence (Chen et al., 2012), this suggested an oncogenic role of 
SOX2 (Lundberg et al., 2014). 
The physical interaction between Oct4 and SOX2 allow the formation of a heterodimer 
complex that binds to the Nanog promoter along with Klf4 to activate the Nanog gene 
expression, but SOX2 can bind to the Nanog gene even without forming the complex with Oct4. 
The transcription factor SOX2 co-occupies several sites in the genome with Oct4 and Nanog, 
which acts as master regulates of pluripotency (Zhang and Cui, 2014; Lee et al., 2017). Blocking 
the expression of SOX2 and Oct4 in pluripotent stem cells and during the initial stages of 
embryogenesis has terrible developmental consequences (Rizzino and Wuebben, 2016). 
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Figure 3. SOX2 functions in pluripotent stem cells (PSCs). SOX2 factor participates in the 
reprogramming of somatic cells to induced PSC (iPSC) and promotes their self-renewal through 
transcriptional regulation of target genes in conjunction with Oct4 transcription factor 
(Chanoumidou et al., 2017).  
 
Interaction of SOX2 with several cofactors confers upon this factor greater functional 
versatility during developmental processes (Zhang and Cui, 2014). Therefore, SOX2 participates 
in multiple biological process: response to growth factor, tissue regeneration, cell cycle arrest 
leading to apoptotic process, negative regulation of epithelial cell proliferation, positive 
regulation of canonical Wnt pathway, regulation of gene expression by regulation of 
transcription and chromatin organization, positive regulation of cell differentiation, such as 
somatic stem cell and neuronal stem cell maintenance, glial cell fate commitment, osteoblast 
differentiation, endodermal cell fate specification and adenohypophysis, pituitary gland, 
forebrain, and inner ear and eye development (Atoraih et al., 2016). 
SOX2 is expressed in adult cells of numerous tissues, such as progenitors of the brain and 
retina, lens, trachea, tongue epithelium, dermal papilla of the hair follicle, stomach, cervix, anus, 
testis, and progenitors of pituitary gland. The expression of SOX2 in several adult endodermal 
and ectodermal stem cell compartments show that this factor is critical for normal tissue 
regeneration and survival, and the ablation of SOX2+ cells in mice results in a disruption of 
epithelial tissue homeostasis and lethality (Arnold et al., 2011). 
Several genes are regulated by SOX2, such as c-Myc that promotes cell proliferation, 
regulates cell growth, apoptosis and self-renewal of stem cells, Wnt1 involved in oncogenesis 
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and development processes, Wnt2 that is essential in carcinogenesis of the esophagus and 
increases metastatic propensity in pancreatic cancer, Klf4 involved in stem-like capacity, EGFR 
that modulate DNA synthesis, cell proliferation, cell migration and adhesion, Oct4 that regulates 
pluripotency and cell differentiation, and TGF-β that is important to control tumor progression 
and metastasis (Liu et al., 2013). 
SOX2 was relevant to several signal pathways directly through its targets or indirectly 
through its interaction with proteins. The FGFR, IL-4/STAT6, and EGFR/Scr/AKT signal pathways 
regulated SOX2 expression directly and EGFR/PI3K/AKT pathway also regulated SOX2 
expression, but the upstream molecule of SOX2 was TGF-α (Liu et al., 2013). The FGFR pathway 
regulates SOX2 expression through two signalling cascades, MEK/ERK pathway that regulates 
SOX2 expression through the final phosphorylation of ERK, which translocated into the nucleus 
and activates the transcription of SOX2, and PI3K/AKT/mTOR cascade regulates positively the 
expression of this factor through the activation of the mammalian target of rapamycin complex 
1 (mTORC1). The inhibition of mTORC1 in glioma stem cells lead to an inhibition of the SOX2 
expression and in self-renewal activity (Garros-Regulez et al., 2016).  
SOX2 protein regulates cell growth and tumor invasion through several signalling pathways, 
such as MAP4K4 (mitogen-activated protein 4 kinases 4), Wnt (Wingless-related integration 
site)/β-catenin, PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B), ERα (estrogen 
receptor alpha), BMP (bone morphogenetic protein), Notch, JAK/STAT3, and EGFR signalling 
pathways, forming a complex regulatory network, suggest that SOX2 plays an important role in 
cell and tumor biology (Atoraih et al., 2016; Chanoumidou et al., 2017). Others signal pathways 
regulated by SOX2 through its targets or interacting partners are VEGF, p53, ErbB, and cell 
surface receptor linked signal transduction (Liu et al., 2013). 
Vilas and colleagues observed an increase of SOX2 expression in mouse embryonic 
fibroblasts (MEFs) immortalized by targeting p53 with shRNA (shp53), especially when MEFs 
deficient in Rb or p130 proteins. In i4F-MEFs (MEFs expressing the four reprogramming factors, 
Oct4, SOX2, Klf4 and c-Myc) SOX2 levels increased upon knockdown of p53, suggesting that 
decreasing p53 levels amplifies the already deregulated SOX2 expression. The increased levels 
of SOX2 were produced from the endogenous SOX2 locus, but not from the transgene locus. 
When p53 is downregulated the low-level SOX2 expression would be sufficient to activate its 
own endogenous transcription. This point to a novel function of p53 repressing SOX2 in 
differentiated cells (Vilas et al., 2015). 
Overexpression of SOX2 in WT MEFs cells, but not p53-deficient MEFs lead to a cell growth 
arrest associated with an increase in the levels of p16Ink4a (p16) and p19Arf (encoded by 
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alternative reading frames of the Ink4a/Arf locus, also known as Cdkn2a (Marqués-Torrejón et 
al., 2013). 
In A549 cells the silence of SOX2 by RNA interference could reduce the tumorigenic 
property of these cells with decreased expression of c-Myc, Wnt1, Wnt2, and Notch (Liu et al., 
2013). 
SOX2 has an important role in vivo and in vitro in the survival and proliferation of cancer 
cells and is a potential candidate biomarker for targets intervention in several cancer types (Ren 
et al., 2016). 
 
 
2.1.1 SOX2 is a key factor in stemness and embryonic development 
SOX2 is a master factor in the maintenance of pluripotency and stemness. This factor is 
required early in embryonic development to maintain pluripotency and self-renewal in 
embryonic stem cells (ESCs) and regulates the formation of several epithelia during fetal 
development (Arnold et al., 2011; Seo et al., 2011). SOX2 expression is initially detected in cells 
at the morula stage, becoming more specifically expressed in the inner cell mass (ICM) and 
trophectoderm of the blastocyst during the latter stages (Zhang and Cui, 2014; Zhou et al., 2014; 
Rizzino and Wuebben, 2016). During the embryonic development the expression of this factor 
is extinguished in most tissues, but it remains strongly expressed in stem cells of the central 
nervous system (CNS), retina, and the primordial gut and have an essential role in the 
maintenance of undifferentiated lineage progenitors such as neural stem cells (Seo et al., 2011; 
Rizzino and Wuebben, 2016). 
 SOX2-null embryos die after implantation due to a failure to form a pluripotent epiblast, 
and blastocyst outgrowths from only trophectoderm-like cells (Zhou et al., 2014). Depletion of 
SOX2 by gene-knockout or RNA interference compromises the pluripotent stage of mouse and 
human ESCs as shown by changes in cell morphology, loss of pluripotent marker expression, and 
differentiation primarily into trophectoderm. In SOX2-null mouse ESCs the overexpression of 
Oct4 can rescue the pluripotency of these cells, suggesting that SOX2 is important in the 
maintenance of pluripotent ESCs through promoting and maintaining Oct4 expression (Zhang 
and Cui, 2014). SOX2 overexpression in embryonic stem cells (ESCs) induce differentiation 
towards the neuroectodermal lineage, and the expression of this gene is maintained in the 
developing neuroectodermal (Zhou et al., 2014), but the deletion of this factor in ESCs results in 
inappropriate differentiation into trophectoderm-like cells (Arnold et al., 2011).  
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Levels of SOX2 expression need to be tightly regulated to maintain pluripotency of stem 
cells because increases or decreases in SOX2 expression lead to the loss of pluripotency. Both 
low and higher levels of SOX2 reduce the promoter/enhancer activity of SOX2-Oct4 target genes. 
The core transcriptional regulatory formed by SOX2, Oct4, and Nanog is important in the 
differentiation of ESCs to specific lineages and to maintain the self-renewal of pluripotent stem 
cells in mouse and human ESCs (Zhang and Cui, 2014; Chanoumidou et al., 2017).  
Heterozygous SOX2 mice are phenotypically normal, although the pituitary size, hormone 
production, and testicular size are reduced. This suggests that SOX2 seems is a central regulator 
for early Pluripotent Stem Cells (PSCs) formation and embryonic development. Mice deficient 
SOX2 expression present eye defects, hearing loss, and abnormal development of the 
hypothalamo-pituitary system (Chanoumidou et al., 2017). 
SOX2 is expressed at high levels in ESCs and its expression is downregulated upon 
differentiation to endoderm or mesoderm while is maintained in the neuroectodermal lineage. 
This shows that the transcriptional regulation of SOX2 is complex (Zhou et al., 2014). SOX2 is 
involved in the differentiation and morphogenesis of esophagus, trachea, and lung, whereas its 
reduction leads to the abnormal development of lung, esophageal atresia, and tracheal-
esophageal fistula defects (Chanoumidou et al., 2017). 
The conserved expression profile of SOX2 during development and adulthood suggests its 
involvement at the establishment and proper function of the Central Nervous System (CNS) 
(Chanoumidou et al., 2017). In neural progenitors cells (NPCs), SOX2 is considered a 
transcriptional activator as well as a repressor inhibiting the expression of target genes directly 
or indirectly, such as genes associated with mitosis. In these cells, this factor is upregulated and 
its expression decreases after differentiation to post-mitotic neuronal and glia cells, thus SOX2 
is important to maintain the self-renewal of NPCs in vitro and in vivo. SOX2 is also essential in 
the preservation of NSC properties, such as proliferation, self-renewal, and neurogenesis (Zhang 
and Cui, 2014; Chanoumidou et al., 2017). SOX2 factor is able to reprogram alone somatic cells 
to induced neural stem cells (NSC) further demonstrates the essential function of SOX2 in these 
cells (Chanoumidou et al., 2017). It has been reported that the cell cycle regulators E2f3a and 
E2f3b regulated SOX2 expression and control the proliferation in NPCs, thus affecting adult 
neurogenesis (Zhang and Cui, 2014).  In neural stem cells (NSCs), p21 inhibits the expression of 
SOX2 gene by directly binding to the SOX2 regulatory region 2 (SRR2) enhancer downstream this 
gene. This suggests that the modulation of SOX2 levels by p21 could be a regulatory mechanism 
to control the proliferation of NSC populations in the adult brain. In p21-null cells increased 
levels of DNA damage are associated with SOX2 overexpression. To maintain a proper regulation 
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of cell-cycle transitions in NSCs is essential the repression of SOX2 gene by p21  (Marqués-
Torrejón et al., 2013). 
SOX2 is also implicated in mesenchymal stem cells (MSC) function, such as positively 
regulation of cell cycle progression by facilitating G1/S transition through transcriptional 
activation of cyclinD1 and c-Myc (Chanoumidou et al., 2017). 
During the development, SOX2 protein may recruit different partner proteins to realize 
diverse regulatory functions in specific biologic contexts and targeting several genes involved in 
development. The complex SOX2-Oct4, in human and mouse, is responsible for targeting genes 
involved in maintenance of pluripotency in embryonic stem cells such as SOX2, Oct4, Nanog, 
Fgf4, and Uff1 and is expressed in inner cell mass, embryonic stem (ES) cells, induced pluripotent 
stem (iPS) cells, pre-implantation embryo, and hindbrain. The function loss of this complex leads 
to defects in implantation (Zhang and Cui, 2014; She and Yang, 2015).  
Binding of SOX2 to Pax6 (paired-box protein 6) is important for initiate lens development 
by targeting SOX2, Pax6, and δ-crystallin genes. This complex is expressed in retina, optic cup, 
and lens and function loss of this interaction causes disruptions in eye development. In neural 
primordial cells, the complexes SOX2-Pou3f2 and SOX2-Brn2 regulates genes, such as SOX2, 
Nestin, and Shh, and the cooperation between SOX2 and Chd7 are involved in the regulation of 
neural stem cells. Many other partners are involved in olfactory placode developments and in 
hair cell formation (Table 1) (Zhang and Cui, 2014; She and Yang, 2015). 
SOX2 is very important in both the establishment and maintenance of pluripotent stem 
cells and its signalling is critical during fetal development for the formation of several 
endodermal and ectodermal tissues, such as nervous system, lens epithelium, retina, sensory 
cells of the taste bud, inner ear, and anterior foregut endoderm. Thus, the expression of SOX2 
plays important roles at multiple stages of prenatal and postnatal development (Arnold et al., 
2011), this suggest that SOX2 seems to be critical for tissue regeneration and survival later in life 
(Rizzino and Wuebben, 2016). 
SOX2 is the only factor that is commonly expressed between ESCs, fetal progenitors, and 
adult stem cells, and may therefore point toward molecular similarities in the regulation of 
pluripotent and different adult stem cells (Arnold et al., 2011). SOX2 is a master regulator of 
stemness and its function is indispensable for the establishment of pluripotent ESC in vivo and 
the generation of iPSC in vitro (Chanoumidou et al., 2017). 
Several enhancers/regulatory regions of SOX2 work together to regulate the expression of 
this gene from early preimplantation embryos to various neural progenitor cells. SOX2 is a key 
factor in the formation of pluripotent cells in early embryos and finally an essential factor for 
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embryonic development because this factor regulates distinct target genes involves in these 
processes (Zhang and Cui, 2014). 
The distinct functions of SOX2 depend on many factors, such as expression levels, 
extracellular signalling, antagonism with tissue specific transcription factors, and partners 
selection in specific cells and development stages (Chanoumidou et al., 2017). This factor can 
participate in transcriptional activation or repression depending on the co-factor recruited for 
the SOX2-partner factor complex. SOX2 knockdown will affect occupancy by the second factor 
leads to inhibition of development progression if this factor do indeed function as pioneers 
(Kamachi and Kondoh, 2013). 
 
Table 1. Example of SOX2 factor partners in the development with target genes and functions (Kamachi 
and Kondoh, 2013; Zhang and Cui, 2014; She and Yang, 2015). 
Partner 
proteins 
Target genes Cell/tissues types Functions Loss-of-function 
phenotype 
Oct4 SOX2, Oct4, 
Nanog, Fgf4, 
Utf1, Fbxo15, 
Lefty1, 
Nmyc1, Rex1, 
Tcf3, DppA4, 
Trp53, Rest, 
Zfp42  
Inner cell mass;  
Embryonic stem (ES) cells; 
Induced pluripotent stem 
(iPS) cells; 
Preimplantation embryo; 
Hindbrain 
 
Maintain 
pluripotency 
Defects in 
implantation 
PAX6 SOX2, Pax6, 
δ-crystallin, 
N-cadherin 
Retina; 
 Optic cup; 
 Lens 
Initiate lens 
development 
Disruptions in 
eye development 
Pou3f2 SOX2, Nestin, 
Shh 
Neural progenitor; 
Neural tube 
Regulation of 
neural 
primordial cells 
Septo-optic 
dysplasia 
Eya1, 
Six1 
Sostdc1, 
Atoh1 
Hair cell progenitors; 
Inner ear; 
Neurogenic placode 
Hair cell fate 
determination 
Defects in hair 
cell formation; 
Defects in 
neuronal 
progenitor 
proliferation 
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Chd7 Jag1, Gli3, 
Mycn 
Neural stem cells  Regulation of 
neural stem 
cells 
Anophtalmia 
esophageal-
genial syndrome 
 
 
 
2.1.2 SOX2 is regulated at translational and post-translational level 
SOX2 expression and activity are regulated at translational and post-translational level, and 
these modifications are important for the several functions of SOX2 (Liu et al., 2013; Zhang and 
Cui, 2014; Lee et al., 2017). The mediators of SOX2 regulatory network include various 
transcriptional factors, microRNA, and epigenetic and signalling pathway regulators 
(Chanoumidou et al., 2017). 
MicroRNA (miRNA) are small (approximately 22-nucleotides) noncoding RNAs that regulate 
the expression of many genes by targeting their mRNAs post-transcriptionally. This binds to the 
partially complementary targets sites in 3’-untranslated regions of mRNAs, inducing mRNA 
degradation or translational inhibition. Expression profile of microRNA (miRNA) is different in 
normal tissues and tumors, and can act as tumor suppressors or oncogenes (Otsubo et al., 2011). 
MicroRNA could inhibit SOX2 at translational level, for example the miRNA-145 through direct 
repression of Oct4, SOX2, and Klf4 could inhibit human embryonic stem cells (ESCs) self-renewal 
and expression of pluripotency genes by targeting the 3’-untranslated region, this promotes 
lineage-restricted differentiation (Otsubo et al., 2011; Liu et al., 2013). In mouse, the miRNA-
134 repress SOX2 expression by targeting its coding region (Otsubo et al., 2011). 
In human gastric carcinoma tissues, the expression of SOX2 was frequently downregulated, 
where 16% it was due to aberrant DNA methylation (Otsubo et al., 2011). Otsubo and colleagues 
demonstrated that miRNA-126 could inhibit SOX2 expression by targeting two binding sites in 
the 3’ untranslated region of SOX2 mRNA through gain-and loss-function assays (Otsubo et al., 
2011). 
SOX2 protein can be modified through phosphorylation, acetylation, ubiquitination, 
methylation, and SUMOylation, these modifications make SOX2 have different activities (Figure 
4) (Liu et al., 2013; Zhang and Cui, 2014). 
SUMO (small ubiquitin-like modifier) modifications has been recognized as an ubiquitous 
and critical post-translational modifier observed in organisms of the eukaryotic kingdom. The 
consequence of this process ranges from the repression of transcriptional factors, to alterations 
of subcellular localization and activity of targets proteins, to DNA damage repair and signal 
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transduction (She and Yang, 2015). Through SUMOylation, mouse SOX2 could be modified at 
lysine247 and the SUMOylation in this lysine or carboxyl terminus impaired the SOX2 binding to 
the Fgf4 enhancer, therefore, transcriptional activities of SOX2 were negatively regulated 
through impaired DNA binding (Liu et al., 2013). SUMOylation of SOX2 impairs transcriptional 
activity and compromises pluripotency (Borkent et al., 2016). Other authors report that lysine47 
residue of this protein located in DNA binding domain could be acetylated by a histone 
acetyltransferase, p300/CBP, and this promoted the nuclear export of SOX2. The increased 
levels of acetylated SOX2 leads to ubiquitination and proteasomal degradation of this 
transcriptional factor (Liu et al., 2013).  
AKT can phosphorylate SOX2 on threonine118 and this regulates the activity of this 
transcriptional factor. The phosphorylation of SOX2 increases its protein stability by blocking 
ubiquitin-mediated proteolysis, but without affecting translocation. This activity of AKT 
regulates SOX2 function and contributes to self-renewal of embryonic stem cells (ESCs) (Jeong 
et al., 2010). The phosphorylation of serine249, 250, and 251 in SOX2 protein promotes 
SUMOylation, inhibiting the binding of the protein to DNA motives (Zhang and Cui, 2014). 
Interactions between SOX2 and CARM1 (coactivater-associated arginine methyltransferase 1) is 
required to maintain the identity of ESCs. CARM1, is a protein with arginine methyltransferase 
activity which facilities the transactivation mediated by SOX2 through methylation on 
arginine113 of SOX2 (Liu et al., 2013). 
SUMOylation of SOX2 protein at lysine247 of its HMG domain interferes with its DNA-
binding activity; acetylation of SOX2 at lysine75 leads to nuclear export followed by 
ubiquitination (Jeong et al., 2010; Lee et al., 2017), because the suppression of SOX2 acetylation 
at lysine75 residue prevents nuclear translocation of this protein (Lee et al., 2017). SOX2 may 
also be phosphorylated at serine249, serine250 and serine251 (Jeong et al., 2010). 
Upregulation of SOX2 acetylation decreases the expression of SOX2 by ubiquitation and 
proteasomal degradation, suggesting that acetylation of SOX2 is a key modulator of SOX2 
functionality (Lee et al., 2017). 
 Activities of SOX2 are multiple through translational and post-translational modifications 
and thereby regulate pluripotency and differentiation (Liu et al., 2013). 
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Figure 4. Multiple modifications in SOX2 for regulate its functions. SOX2 can be modified at level 
translational by miRNAs and at level post-translational through phosphorylation, acetylation, 
ubiquitination, methylation, and SUMOylation. These changes make SOX2 have different activities (Liu et 
al., 2013). 
 
 
2.2 Role of SOX2 in cancer 
SOX2 is one of the key members of the SOX family and play an important role in 
carcinogenesis of several tumors, including gastric, breast, and pancreatic cancers (Li et al., 
2015). This factor is overexpressed in many aggressive tumors and its role as oncogene in 
malignant proliferation once promote tumor proliferation and growth, maintenance of 
stemness, cellular migration, invasion, metastasis, tumorigenesis and maintenance of 
tumorigenicity, apoptotic resistance, and chemoresistance (Liu et al., 2013; Ren et al., 2016). 
Overexpression of Oct4, SOX2, and Nanog genes has been detected in breast, head and 
neck, and prostate cancers. These genes are important for tumorigenicity, metastasis, and 
radioresistance (Atoraih et al., 2016).   
Amplification of SOX2 gene was detected in 21% of all primary head and neck squamous 
carcinomas (HNSCC) and, in this carcinoma, SOX2 is associated with resistance to apoptosis-
inducing agents including cisplatin though the ability to induced the expression of the 
antiapoptotic protein BCL-2 (Schröck et al., 2014). Knockdown of SOX2 lead to significant 
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inhibition of HNSCC with cancer stem cells (CSC) stemness-associated features, including self-
renewal capacity, stem cells expression markers, invasion capacity, chemoresistance, and 
tumorigenesis (Sang Hyuk Lee et al., 2014). Siegle and colleagues identified several novel SOX2 
binding partners in human head and neck squamous cell carcinomas (SCCs) that directing SOX2 
activity to numerous genomic loci and can function as both a transcriptional activator as well as 
a repressor (Siegle et al., 2015). In this type of cancer, SOX2 promotes the proliferation via 
upregulate cyclin B1 expression (Sang Hyuk Lee et al., 2014). 
In humans, mutations in SOX2 gene have associated to anophthalmia and hypopituitarism, 
and sometimes to learning difficulties, convulsions, motor dysfunctions, and growth problems 
(Li et al., 2012; Garros-Regulez et al., 2016). However, SOX2 is upregulated in several types of 
human cancers, such as medulloblastoma, glioblastoma, breast, gastric and lung cancers, 
osteosarcomas, and squamous cell carcinomas (Herreros-Villanueva et al., 2013). SOX2 
expression is increased in gliomas and glioblastomas in the initial phase and the highest levels 
are associated with poor outcome.  Silencing of SOX2 gene decreases cell proliferation and might 
be a novel therapeutic approach to fight against brain tumors (Marqués-Torrejón et al., 2013; 
Garros-Regulez et al., 2016). 
Liu and colleagues discussed that in tumor initiating cells (TICs) derived from adult human 
glioblastoma SOX2 knockdown lead to inhibition of proliferation and loss of tumorigenicity in 
immunodeficient mice, indicating that this factor is essential for maintaining the self-renewal 
capacity of TICs and SOX2 or its downstream molecules might be an ideal target for glioblastoma 
therapy (Liu et al., 2013). 
In pancreatic cancer cells the increased expression of SOX2 is sufficient for cell proliferation 
(G1 for S phase transition) by inducing expression of cyclin D3 and repression of p21Cip1 and 
p27Kip1. On the other hand, the suppression of SOX2 maintains the cells in the G0/G1 phase, 
which is associated with the expression of p21 and p27. Thus, SOX2 protein can facilitate the cell 
cycle progression in pancreatic cancer cells through regulation of cyclin D3, CDK6 activation, and 
repression of p21Cip1 and p27Kip1  (Herreros-Villanueva et al., 2013). In colorectal cancer cells, p21 
can directly bind to Cdk1/cyclin B1 and inhibits its activity (Sang Hyuk Lee et al., 2014). 
Repression of SOX2 induces cell apoptosis via cleavage of caspase-3 and activation of 
specific pro-apoptotic factors and inhibit G1/S transition in prostate cancer by regulating cyclin 
E and regulating cyclin D1 in breast cancer (Ren et al., 2016). In this type of cancer silence SOX2 
expression decreased the tumor cell proliferation and colony formation (Liu et al., 2013). 
In Ewing’s sarcoma, the suppression of SOX2 induce G1/S cell cycle arrest by targeting p21, 
p27, and cyclin E. The repression of cyclin E and activation of p21 and p27 leads to inhibition of 
SOX2. SOX2 inhibition promotes the cell apoptosis via the activation of extrinsic and intrinsic 
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apoptotic pathways through activation of caspases-8 and -9, increased of pro-apoptotic protein 
Bad and Fas, and decreased of anti-apoptotic protein Bcl-2 and XIAP (Ren et al., 2016). 
The overexpression of SOX2 in gastric cancer cells decreased the levels of cyclin D1 (Otsubo 
et al., 2008), influencing the cell cycle progression (Han et al., 2014), reduced the Rb 
phosphorylation, and increased the levels of p27 protein. The expression of SOX2 gene is 
downregulated and exogenous expression of SOX2 inhibits cell growth by dragging cell cycle and 
apoptosis. Thus, SOX2 gene work as a tumor gene suppressor in gastric cancers (Otsubo et al., 
2008). Hütz and colleagues refer that in gastric cancer cells, the inhibition of SOX2 by cellular 
transfection decreases cell proliferation and RNA analysis reveals the increased in quantity of 
p21 (Hütz et al., 2014). However, in human gastric carcinoma, SOX2 promoter are silenced by 
DNA methylation (Karachaliou et al., 2013). 
SOX2 is overexpressed in 11% of the tumors in colorectal cancer (CRC) and is associated 
with BRAFV600E mutation, but not to K-Ras mutations in codon 12 and 13. The expression of SOX2 
and BRAFV600E mutated are associated with poor patient survival and blocking downstream BRAF 
(B-Raf) signalling using an MEK-inhibitor resulted in a decreased expression of SOX2, suggesting 
that SOX2 expression is at least partly regulated by the BRAF/MEK pathway (Lundberg et al., 
2014). 
In 90% of lung squamous cell carcinoma the SOX2 mRNA expression is increased and 
associated with poor prognosis, and when SOX2 is silenced the BMP4 factor inhibits cell 
proliferation (Liu et al., 2013; Fang et al., 2014). SOX2 is also overexpressed in non-small cell 
lung carcinoma (NSCLC)  (Ying et al., 2016), where SOX2 and Oct4 are exclusively expressed in 
the nuclei of human NSCLC cells and the expression of Oct4 was associated with poor prognosis 
of lung cancer, we can conclude that this transcription factors are a promising marker in 
diagnosis and therapy of this cancer (Liu et al., 2013). 
About of 27% samples of human small-cell lung cancer (SCLC) have the SOX2 gene amplified 
and SOX2 knockdown blocked the proliferation of this cell lines and decreases anchorage-
independent growth. (Liu et al., 2013; Sang Hyuk Lee et al., 2014). Amplified SOX2 in some types 
of cancer leads to high levels of this factor (Liu et al., 2013). SOX2 gene it also amplified in skin 
squamous cell carcinoma and deletion of this gene in mouse epidermal cells reduce the tumor 
formation in this tissue (Boumahdi et al., 2014). SOX2 factor is also essential for cutaneous 
squamous cell carcinomas (SCC) growth in mouse and human, the function of this protein as a 
key molecule in SCCs because it acts as an integration point of development and oncogenic 
signalling mechanisms (Siegle et al., 2015). 
In glioma stem-like cells (GSCs) SOX2 is overexpressed and promote the stemness, 
migration, invasion, and maintenance of tumorigenicity, however has not been performed an 
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exhaustive analysis of SOX2-regulated molecular circuits in GSCs. In GSCs, SOX2 plays prominent 
roles in driving the growth, treatment resistance, and recurrence of glioblastoma (Acanda de la 
Rocha et al., 2016). Downregulation of SOX2 by RNA interference (siRNA) decrease proliferation 
and ability to form tumors in vivo and silencing SOX2 leads to reduction of migration and 
invasion capabilities, increases senescence, and produces an arrest of the cell cycle in G0/G1 
(Garros-Regulez et al., 2016). 
Silencing of SOX2 in lymph node showed a decreased ability in cell migration and invasion 
in vitro and a reduction of tumor metastasis in vivo (Schröck et al., 2014). 
Xia and colleagues refer that in lung adenocarcinoma, the overexpression of SOX2 can 
inhibit K-Ras activation in cancer formation. This type of cancer requires reduced SOX2 
expression for your formation (Xu et al., 2014). 
Transcription factors Oct4 and SOX2 demonstrate clinical importance in cervical cancer, by 
the correlation between poor prognosis in patients and overexpressed levels of Oct4 and loss of 
SOX2. In lung cancer, the high expression of SOX2 is correlated with low patient survival, but in 
esophageal squamous cancer the low expression of SOX2 is associated with poor prognosis (Lee 
et al., 2017). 
The fact that there are studies showing contradictory effects of SOX2 on cell proliferation 
suggests that this transcription factor has a different role depending of the cancer type (Weina 
and Utikal, 2014). So, SOX family can act as an oncogene, tumor suppressor, or both depending 
on the cellular context (Thu et al., 2014).   
In cancer cells, the SOX2 protein is involved in proliferation and cellular growth, cell 
migration and invasion, stemness and tumorigenicity, resistance to signals of apoptosis and 
therapy, metastasis and tumorigenesis (Liu et al., 2013; Weina and Utikal, 2014). 
SOX2 was identified as a regulatory factor in several key signalling pathways associated with 
tumor progression, including AKT, Wnt, and MAPK cascades (Ren et al., 2016). In laryngeal 
cancer cells SOX2 promotes the migration and invasion through the induction of MMP-2 and 
PI3K/AKT/mTOR pathway (Yang et al., 2014) and in Ewing’s sarcoma SOX2 regulated cell-cycle 
progression and apoptosis via activation of the PI3K/AKT signalling pathway. The signalling 
pathway play an important role in cell survival and cell growth via direct or indirect regulation 
of apoptotic factors and cell cycle regulators (Ren et al., 2016). 
Li and colleagues refer that SOX2 overexpression can contribute to chemoresistance to 
paclitaxel (chemotherapeutic agent) in ovarian cancer through of PI3K/AKT signalling pathway. 
Chemoresistance cells present a higher expression of SOX2 and the silencing of SOX2 decreased 
the expression levels of PI3K, AKT, and p-AKT, suggesting that SOX2 directly regulates the 
PI3K/AKT pathway, and induce apoptosis mediated by paclitaxel. In addition the knockdown of 
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SOX2 lead to decrease of cell proliferation, for that the transcription factor SOX2 will become an 
important indicator for ovarian cancer prognosis and a potential target for ovarian cancer 
therapy (Li et al., 2015).  
In breast cancer, SOX2 transcription activity was responsible for the tumorigenicity and 
cancer stem cell-like phenotypes (Liu et al., 2013), and SOX2 overexpression is associated with 
resistance to endocrine therapy with tamoxifen in the resistant tumor cells. Downregulating 
SOX2 expression leads to Wnt signalling decreased and thus re-sensitized the resistant cells to 
tamoxifen, this suggest that SOX2 is involved in the Wnt signalling in cancer stem cells (Lee et 
al., 2017). 
In human prostate cancer cells, SOX2 overexpression promotes cell proliferation and 
prevent the cell cycle arrest induced by paclitaxel. The inhibition of the PI3K/AKT signalling 
pathway attenuated the effects of SOX2 during the treatment with paclitaxel (Li et al., 2014) 
During the carcinogenesis, SOX2 can cooperate in the loss of differentiation of the cancer 
cells and in maintaining the stem cell  phenotype in the same (Hussenet et al., 2010). In 
squamous epithelial cancers, this transcription factor has been implicated as a driver through 
gene amplification and in prostate cancer is a marker of neuroendocrine differentiation (Mu et 
al., 2017). 
Mu and colleagues show that prostate tumors with intact TP53 and RB1 genes are likely to 
acquire resistance by restoration of androgen receptor (AR) signalling, whereas cancers with 
deficient TP53 and RB1 are more likely to escape therapy by transitioning away from an AR-
dependent luminal identity through the reprogramming activity of SOX2 (Mu et al., 2017). 
SOX genes are regulators of cellular programming, which means that any disruption of 
these genes may lead to several human diseases (Thu et al., 2014). The SOX2 protein has been 
associated with numerous types of tumours, and in some cases described as an oncogene and 
controls the physiology of cancer cells while promoting oncogenic signalling and the 
maintenance of cancer stem cells (Weina and Utikal, 2014). Thus, as SOX2 is expressed in 
multiple types of cancer is considered an ideal therapeutic target (Karachaliou et al., 2013), since 
the high expression of this factor in primary tumor could profit from more aggressive primary 
therapy strategies (Schröck et al., 2014). 
High levels of SOX2 expression have been associated with tumor aggressiveness and worse 
prognosis (Garros-Regulez et al., 2016). Wang and colleagues refer that is need more 
investigation to know the specific role of SOX2 in tumor-associated signalling pathways (Wang 
et al., 2015). 
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3. The oncogene Ras 
Ras superfamily is composed of more than 150 proteins (Fernández-Medarde and Santos, 
2011) divided in five families: Ras, Rho, Arf/Sar, Ran, and Rab, and all proteins have a common 
domain- G-domain when found the GTP binding region (Rojas et al., 2012).  
The monomeric Ras proteins are a small guanosine triphosphate hydrolyzing proteins 
(GTPases) (Asati et al., 2016a; Ilinskaya et al., 2016) with a molecular weight of 21 KDa 
(Kubuschok et al., 2006) and these proteins are the transcription product of Ras gene, a proto-
oncogene (Manchado et al., 2016). 
The H-ras (Harvey rat sarcoma viral oncogene homolog), N-ras (Neuroblastoma rat sarcoma 
viral oncogene homolog), and K-ras (Kirsten rat sarcoma viral oncogene homolog) genes are the 
three human Ras genes (Baines et al., 2011).  
These small GTPases is regulated by GTP/GDP cycle, Ras is inactive when GDP (guanosine 
diphosphate) is bound to C-terminal, but when stimulated by GEF (guanine nucleotide exchange 
factor) released GDP and GTP (guanosine triphosphate) binds to Ras protein, becomes active. 
However, when GTP is hydrolyzed in GDP by GTPase Ras protein converts to inactive form. If any 
mutation blocks this cycle by inactivation the GTPase activity, Ras protein remains active (Baines 
et al., 2011; Rojas et al., 2012; Logsdon and Lu, 2016).  
Ras family members are highly conserved across species (Castellano and Downward, 2011) 
and the signalling of this oncogene can be observed on intracellular membranes, such as 
cytoplasm, endosomes, endoplasmic reticulum, Golgi apparatus, and mitochondria (Baines, et 
al., 2011). Since their localization and capacity to regulated different members of the same 
family and these selective interactions, Ras family are involved in regulation of multiple 
biological functions (Castellano and Downward, 2011), such as macromolecular biosynthesis, 
organization of the cytoskeleton, nuclear transport, vesicular trafficking (Asati, et al., 2016a), 
regulation of growth, apoptosis, senescence, differentiation of several types of cells, and anti-
cancer effect, by participating in cell proliferation and differentiation via its intrinsic GTPase 
activity by the transmission of signals initiated  in the plasma membrane (Kubuschok et al., 2006; 
Fernández-Medarde and Santos, 2011; Salzano et al., 2014). Alterations in these pathways can 
have severe consequences and can result in several abnormalities, including tumorigenesis and 
immunological disorders (Asati et al., 2016a).  
Ras protein is commonly not active until called upon by external cellular signals, but when 
activated it can influence several cellular functions (Logsdon and Lu, 2016). The functional 
differences that Ras exhibit are, possibly, associated to with hyper-variable C-terminal region 
(HVR) which modulates the interaction Ras/membrane to the different locations in organelles 
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and in signalling cascades (Prior et al., 2012). Ras protein is activated in response to signalling 
pathways initiated by extracellular stimuli and promote binding to numerous effectors proteins 
which result in activation of multiple signalling cascades (Asati et al., 2016a).  
H-ras is an oncogene that promotes proliferation by upregulated general transcription 
factors to stimulate RNA synthesis. Cells overexpressing H-Ras present an increased expression 
of the general transcription factor TATA-box binding protein (TBP) that leads to increase RNA 
synthesis (Kotsantis et al., 2016). 
This proto-oncogene becomes an oncogene when mutated, and is associated with several 
human cancers (Salzano et al., 2014). The oncogenic mutations in Ras affect its GTPase activity, 
causing accumulation of Ras in active state (with GTP bound) and result on hyperactive signalling 
that is responsible for initiation and maintenance of tumorigenesis (Manchado et al., 2016).  
 
 
3.1 Signalling pathways activated by oncogene Ras   
Ras signalling is involved in many cellular functions, such as cell proliferation, apoptosis, 
migration, fate specification, and differentiation. This oncogene activates several signalling 
pathways, which includes the Raf/MEK/ERK mitogen-activated protein kinase (MAPK), 
phosphoinositide 3-kinase-AKT-mTOR (PI3K), and RAL (Castellano and Downward, 2011; Asati et 
al., 2016b). 
Interaction of activated Ras with Raf initiates the Raf/MEK/ERK pathway and the activation 
of ERK causes phosphorylation of multiple substrates, as kinases that control translation (for 
example p90) and transcription factors that control genes involved in cell cycle (for example 
ElK1, Fos, Myc) (Overmeyer and Maltese, 2011; Lee et al., 2017). Therefore, Raf/MEK/ERK 
cascade is the pathway responsible for transmitting Ras mitogenic signals to the cell cycle 
machinery (Drosten et al., 2014). The activation of Ras/Raf/MEK/ERK pathway is essential for 
cell proliferation since this cascade play a critical role in the transmission of signals from growth 
factor receptor to regulate gene expression, and its inhibition blocks the cell cycle at the G1 
phase, which can lead to cellular apoptosis (Drosten et al., 2014; Asati et al., 2016b). However, 
the retroactivation of the Raf/MEK/ERK cascade promotes the cell proliferation (Drosten et al., 
2014). In vitro studies show that there is an increased of Ras expression during the G1 and S 
phase of cell cycle (Morais et al., 2008; Prior et al., 2012). 
Drosten and colleagues refer that in normal cells (MEFs), Ras signalling activated the MAPK 
cascade, which result in inactivation of the p53/p21Cip1/Rb tumor suppressor axis via 
acetylation of lysine161/162 residues, and consequently allows the cell proliferation. Cells 
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lacking Ras, the inactivation of Raf/MEK/ERK pathway leads to activation of p53 through 
acetylation of lysine161/162 residues. The activation of p53 induces p21Cip1 expression that 
activates Rb and induce the cell cycle arrest. Cells deficient in Ras proteins and with 
p53/p21Cip1/Rb axis inhibited by absence of p53, leads to retroactivation of the Raf/MEK/ERK 
cascade and sustained cell proliferation (Drosten et al., 2014). 
The PI3K (phosphatidylinositol 3-kinase) – PKB (protein kinase B)/AKT cascade controls 
cellular processes that are critical for cancer progression, such as cell survival (apoptosis 
inhibition), transcription, cell cycle progression, translation, metabolism, and motility 
(Castellano and Downward, 2011; Prior et al.,  2012; Asati et al., 2016b).  In cells stimulates with 
growth factors, PI3K has activated when the cells are transiting from G0 to G1 phase and later 
in G1 phase. This shows that Ras activity is needed throughout all the different phases of cell 
cycle (Castellano and Downward, 2011). 
In vitro studies show that H-Ras protein is the best activator of PI3K while K-Ras has a 
cohesive bound with Raf and Rac (Prior et al., 2012). In human thyroid epithelial cells, PI3K is 
required for the proliferative response to Ras, so PI3K signalling is necessary to supports 
tumorigenesis (Castellano and Downward, 2011). Mutations in K-ras gene leading to 
deregulation of signalling pathways such Ras/Raf/ERK and PI3K/AKT (Fernandes et al., 2016). 
The involvement of various proteins in the Ras signalling pathway becomes more difficult to 
understand this pathway (Asati et al., 2016a).  
Alterations of signal transduction pathways leading to uncontrolled cellular proliferation, 
survival, invasion, and metastasis are the basis of the carcinogenic process. The abnormal 
activation of PI3K/AKT cascade is associated with many human cancers, for example in lung 
cancer (Asati et al., 2016b). The disruption of this pathway promotes oncogenesis because the 
PI3K activates important mediators of Ras-mediated transformation, such as Rac GTPase, a Rho 
family protein. In Ras mutant cells, although multiple Ras effectors are essential to initiate tumor 
formation, the PI3K/AKT signalling is indispensable to maintain tumor growth, PI3K signalling is 
essential for Ras to drive tumor development; however the inhibition of PI3K alone isn’t 
sufficient to cause regression of tumors once established (Castellano and Downward, 2011). The 
resistance of cancer cells to doxorubicin is associated with deregulation of the PI3K pathway 
(Asati et al., 2016b).  
Oncogenic Ras and PI3K can form metastasis by promoting the loss of anchorage-
dependent growth, which is a key feature in tumor cells. Oncogenic mutations that increase 
enzymatic activity, constitutively stimulate AKT signalling, induce growth in culture, and cause 
tumors in vivo (Castellano and Downward, 2011). 
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Deregulation of MAPK cascade is frequently observed in several cancers, such as 
melanoma, pancreatic, lung, colorectal, and breast cancers because this pathway play a central 
role in the carcinogenesis. This cascade is involved in the regulation of many cellular processes 
including proliferation, survival, differentiation, apoptosis, motility, and metabolism  (Asati et 
al., 2016b). In human cells, the interaction between Raf/MEK/ERK and PI3K/AKT pathways is 
important in Ras-mediated transformation because in these cells the inactivation of the MAPK 
pathway using different inhibitors decreases AKT phosphorylation (Castellano and Downward, 
2011). In the presence of apoptotic signals induced by c-Myc, Ras use specifically the PI3K/AKT 
pathway to promote the cell survival (Cox and Der, 2003). 
In tumorigenesis, different mechanisms activate the Ras signalling pathway, such as 
mutations in Ras, loss of GTPase-activating proteins (GAPs), and overexpression of receptor 
tyrosine kinases (RTKs) (EGFR, ERBB2) (Castellano and Downward, 2011). This suggesting that 
inhibition of components of this pathways may be a potential strategy for cancer therapy (Asati 
et al., 2016b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Ras signalling pathways. The Ras/RAF/MEK/ERK cascade is the classic RAS/MAPK pathway 
where RAF binds to the effector region of RAS-GTP, inducing translocation of the protein to the plasma 
membrane. In the PI3K pathway, PIP3 stimulates the AKT/PKB kinase and several Rac-GEFs, such as Sos1. 
Ras also activates the RalGDS pathway signalling to enhance cellular transformation. The activation of PLC 
by Ras leads to break down of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases Ca2+ from intracellular stores, and DAG activates 
protein kinase C (PKC), together altering the activity of cellular proteins. The activation of this oncogene 
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allows the formation of RASSF1-NORE1A complex, activated proapoptotic pathways (Lourenço et al., 
2014). 
 
 
3.2 Role of the oncogene Ras in cancer 
Oncogenic Ras promotes initiation and maintenance of tumor growth (Castellano and 
Downward, 2011), and for this is a powerful tool for investigating the cell origin of different 
cancers (Xu et al., 2014). It is very common to found mutations in one of the three Ras genes (H-
ras, N-ras e K-ras) and aberrant function of Ras is associated with rapid proliferation diseases 
and cancers (Fernández-Medarde and Santos, 2011; Prior et al., 2012). The aberrant activation 
of these proteins facilities all characteristics of the malignant phenotype in cancer cells, including 
cellular proliferation, transformation, invasion, and metastasis (Ilinskaya et al., 2016). 
Studies in the last few years have identified that a single mutation in codon 12 and/or 13 of 
exon 2 and 61 of exon 3 of Ras oncogene are sufficient for tumor formation. These mutations in 
conserved region promote the binding of GTP and maintains Ras active (Fernández-Medarde 
and Santos, 2011; Prior et al., 2012). 
It is possible found mutations in Ras genes in about 33% of all human cancers, but these 
mutations affect, predominantly, the K-ras locus, which is observed in 21,6% of all samples 
analyzed. In contrast, the rate of occurring mutations in N-ras and H-ras is very low (8% and 
3.3%, respectively) (Baines et al., 2011). Because of the high frequency of K-ras mutations and 
the fact that they appear during the initial stage of tumor progression it can be concluded that 
K-Ras plays an important role in human tumorigenesis. In a normal mouse, the K-Ras protein is 
essential for their development unlike the N-Ras and H-Ras proteins are unnecessary 
(Fernández-Medarde and Santos, 2011). Despite the H-ras gene is the isoform less frequently 
mutated in human cancers it is the most studied, while K-ras gene is predominantly mutated in 
three of the four neoplasms that cause more deaths in US: lung, colon, and pancreatic cancers 
with a rate of 86% of all Ras mutations (Baine et al., 2011; Asati et al., 2016a). 
K-Ras protein is mutated, mainly, in pancreatic ductal adenocarcinomas and lung and colon 
cancers, H-Ras in bladder cancers and N-Ras in leukaemia, thyroid carcinomas, and malignant 
melanomas (Fernández-Medarde and Santos, 2011). In 90% of pancreatic cancers K-ras gene is 
mutated (Prior et al., 2012; Logsdon and Lu, 2016). 
In primary culture cells, Ras induces premature senescence and apoptosis. The activation 
of H-Ras and the block of p53 confers mobility to cells of human urothelial cancer and is capable 
of transforming non-invasive cells in invasive cells (He et al., 2015). 
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Mutations on Ras gene are associated with several types of cancer with low success rate 
(Drosten et al., 2014), such as carcinomas of the pancreas, colon, lung, thyroid, and myeloid 
malignancies (Kubuschok et al., 2006; Drosten et al., 2014). 
In colorectal cancer 35-45% of all patients that present K-ras mutations, this exhibited an 
early development and progression, so K-ras mutation become an important prognostic factor 
for determination of the colorectal cancer (Asati et al., 2016a). K-ras gene is mutated in about 
21% to 30% of human lung adenocarcinoma (Mukhopadhyay et al., 2014), activation of K-Ras 
protein is a potential source of heterogeneity, which hinders their therapy (Xu et al., 2012).  
Mutations in Ras pathways that leads to the expression of active Ras proteins, as observed 
in about 30% of human cancers. The Ras/MAPK/PI3K pathway is activated in human squamous 
cancers by different mechanisms, this indicates that K-Ras promotes the development of lung 
cancers (Mukhopadhyay et al., 2014) and the aberrant activation of the Ras/MAPK pathway is 
correlated with cancer progression and metastatic tumor cell growth (Aksamitiene et al., 2012). 
In mouse model with K-Ras lung cancers, the inhibition of MEK and PI3K exhibits anti-tumor 
activity (Shaw et al., 2011).  
In pathological conditions, such as inflammation, Ras activity can lead to senescence, cell 
death or transformation, in absence of tumor suppressors. This condition can initiate a 
carcinogenesis in pancreatic cells expressing endogenous levels of oncogenic mutant K-Ras 
(Logsdon and Lu, 2016). 
In hepatocellular carcinoma (HCC) Ras protein is not mutated, but their activity is elevated 
by alteration of regulatory molecules, such as decreased levels of GTPase-activating proteins 
(GAPs). The decreased of GAPs levels prolonged the Ras signalling that is similarly to the 
oncogenic mutations in ras gene. The overexpression of the oncogenic K-Ras is sufficient to 
transform adult pancreatic acinar cells without external stimulants. That is, the increased of Ras 
levels is capable of cellular transformation without oncogenic mutation (Logsdon and Lu, 2016). 
In pancreatic ductal adenocarcinoma (PDAC), the detection of K-ras mutations possibly can be 
useful prognostic factor for its treatment (Asati et al., 2016a). 
The Rasal2, a Ras GTPases-activating protein (Ras-GAP), which can catalyze GTP into GDP 
and inactivate Ras, acts as a tumor suppressor in bladder cancer (BCa) and modulates the 
phenotypes of cancer stemness and epithelial-mesenchymal transition (EMT) through 
MAPK/SOX2 pathway. The suppression of this protein could facilitate BCa cell migration, 
invasion, stemness, and tumorigenesis and in breast cancer promoted the tumor development 
as a consequence of activating K- and H-Ras. Rasal2 regulated BCa cells stemness and EMT via 
MAPK/SOX2 signalling pathway, in which the transcription factor SOX2 acted as an important 
bridge (Hui et al., 2017). 
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Involvement of Ras in cancer is accentuated by Ras mutations and deregulation of many 
regulators or effector pathways, so the study of oncogenic Ras signalling is essential to establish 
a molecular basis for the pathogenesis of human cancer (Castellano and Downward, 2011), and 
the use of Ras signalling pathways as therapeutic target is attractive, but in the same time 
complicated since these pathways are also essentials for the proliferation and survival of the 
normal cell (Shaw et al., 2011). 
 
 
4. The therapeutic anti-cancer targets  
Cancer is considered a cell cycle disease, once only normal cells proliferate in the presence 
of growth factors and specific mitogenic signals, but the cancer cells proliferated in unregulated 
way (Diaz-Moralli et al., 2013). Genomic alterations, such as changes in oncogenes, tumor 
suppressor genes, DNA mismatch repair, and excision repair genes are involved in the most 
human cancers (Asati et al., 2016a). 
The finding of genetic, genomic, and clinical biomarkers redirected the treatment of cancer 
for a personalized medicine, having consideration a person’s susceptibility/progression of 
disease, the patient’s response to therapy and the toxicity of therapeutic for patient. The 
information from biomarkers permits a rapid disease diagnosis, risk assessment, and better 
clinical decision. For colorectal cancer (CRC) the microsatellite instability (MSI) and mutations of 
K-ras can be biomarkers of “independent” prognostic value in patients (Asati et al., 2016a). 
The increased of CDK (cyclin-dependent kinases) and cyclins expression and loss of CKI 
(cyclin-dependent kinases inhibitor) and pRB expression are changes associated with cancer 
caused by chromosomic abnormalities (amplification and translocation of oncogenes and 
deletion of tumor suppressor genes) or epigenetic inactivation (methylation of suppressors 
tumor promotors) (Diaz-Moralli et al., 2013). Malumbres refers that the inhibition of oncogenes 
and suppressor genes such as “checkpoint” kinases affect cancer cells proliferation (Malumbres, 
2011). 
In cancers induced by changes in ras gene, the CDK4 is a good pharmacological target, 
through its inhibition (Diaz-Moralli et al., 2013) and inhibition of CDK2 to block de cell cycle 
progression from G1 to S phase (Malumbres, 2011). 
The compression about CDK structure permits the development of CDK inhibitors with 
therapeutic effect against cancer. The molecules developed as CDK inhibitors can be divided into 
two groups: those that had a broad-spectrum action, such as flavopiridol, olomoucine, R-
roscovitine, and kenpaullone, and highly specific, such as fascaplysin, riuvidine, purvalanol A, 
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and dinaciclib. In some types of cancers, the sensibility for CDK inhibitors depends on the 
pathogenic-spectrum of mutations. Taxanes and vinca alkaloids are used in breast and ovarian 
cancer therapy since they interfere with microtubules dynamics (Diaz-Moralli et al., 2013). 
The inhibition of an important biological capacity for a cancer, can stop their growth and 
progression, being necessary more investments in drug for specific targets (Hanahan and 
Weinberg, 2011). 
Cancer cells, in repost to a particular therapy, can reduce the dependence on particular 
marker and become more dependent of another marker. For example, angiogenesis inhibition 
in human glioblastomas apparently causes an increase of local invasion and local metastasis. The 
development of drugs that induce the apoptosis may hyperactivate mitogenic signalling of 
cancer cells (Figure 6) (Hanahan and Weinberg, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Therapeutic targeting of the hallmarks of cancer.  Developed drugs that interferes with 
important capabilities for tumor growth and progression (Hanahan  
and Weinberg, 2011). 
 
Ras mutated present highly sensitive to MEK inhibition, these inhibitors act on endothelial 
cell proliferation and tumor cells apoptosis by controlling angiogenesis through increased the 
level of pro-apoptotic protein BIM. MEK162, sunitinib, and axitinib act as angiogenesis inhibitors 
(Asati et al., 2016a). 
Colorectal cancer patients treated with Cetuximab and Panitumumab as monoclonal 
antibodies that inhibit the epidermal growth receptor (EGFR) showed significant improvement 
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in her life, but patient with mutation of codon 12 and 13 in K-ras gene exhibited a lack of 
response to this monoclonal antibodies (Asati et al., 2016a). 
The discovery of K-ras as a clinical biomarker and a therapeutic target has involved the 
scientific community to create effective and precise anticancer drugs for cancer therapy (Asati 
et al., 2016a). 
For the lung adenocarcinoma, the K-Ras mutant is a therapeutic target that represents a 
major goal of clinical oncology. The US Food and Drug Administration (USFDA) approved the 
trametinib that is an MEK inhibitor in Ras/Raf/MEK/ERK cascade. The components Raf, MEK, and 
ERK of the MAPK pathway have been used as Ras target, but this strategy has been harm by 
toxicities associated with their sustained inhibition and/or adaptive resistance mechanisms. 
USFDA also approved for leukemia treatment  the tipifarnib, a Ras inhibitor (Manchado et al., 
2016). 
Other promising tool for the development of anticancer therapy is the use of several 
ribonucleases (RNases), for inhibition of Ras signalling though direct binding. These RNases 
induce selective cytotoxicity in cancer cells by initiated apoptosis (Ilinskaya et al., 2016). The 
development of small molecules that can restore the GTPase activity of mutant Ras proteins is 
other strategy for inhibition Ras signalling (Asati et al., 2016a).  
Combination treatment of non-small cell lung cancer (NSCLC) with gefitinib and specific 
inhibitors of the PI3K/AKT and Ras/ERK pathways can be a successful strategy for the 
development of anti-cancer drugs (Asati et al., 2016a). Recently, a group of investigators 
suggests that PI3K p110α is a good target for therapeutic intervention in colorectal cancer with 
K-ras mutations (Fernandes et al., 2016). 
Cancers with a high prevalence of K-ras mutations are difficult to treat and doesn’t exist an 
effective therapy, thus K-ras gene is a potential biomarker of pancreatic, colorectal, and lung 
cancers (Asati et al., 2016a).  
The resistance to the antiandrogen drug, such enzalutamide, in prostate cancers can be 
reversed by inhibiting SOX2, this raises some hope that appropriate clinical interventions could 
prevent or overcame resistance. Mu and colleagues refer that the direct pharmacologic 
inhibition of SOX2 is not feasible currently, but can be possible to prevent SOX2 transcriptional 
up-regulation following the loss TP53 and RB1. RB1 directly represses SOX2 by recruitment to 
E2F binding sites in the SOX2 promoter and TP53 indirectly inhibits SOX2 by up-regulation of its 
target gene miR-34 that targets SOX2 mRNA (Mu et al., 2017). 
Transplants of glioma stem cells (GSCs) in mice brain using peptide vaccination against SOX2 
increase the mice survival. In these cells, miRNA-145 delivery can suppress the tumorigenicity 
through direct downregulation of SOX2 protein with GSCs becoming more sensitive to 
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chemotherapeutic agents, such as cisplatin. The use of miRNA might improve current cancer 
treatments, especially for tumors that have developed a resistance to conventional therapeutic 
methods. This is a promising therapeutic, but the use of viral vectors for gene delivery may be 
accompanied by multiple problems, including immune response (Garros-Regulez et al., 2016). 
Actuality, approximated 30 different kinases have been identified and multiple inhibitors 
are developed which reached in Phase I clinical trial (Asati et al., 2016b).  
The development of drugs and treatment protocols that cover multiple 
characteristics/marks of cancer cells will be more effective in cancer therapy (Hanahan and 
Weinberg, 2011).  
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Aims 
 
SOX2 is a stem-cell associated transcription factor that has an important role in maintaining 
the unique characteristics of embryonic stem cells, such as clonogenicity, pluripotency, and self-
renewal (Karachaliou et al., 2013). Its overexpression or gene amplification have been 
connected with cancer development in several tissues, such as lung and breast (Liu et al., 2013). 
Thus, SOX2 is a key factor for successful embryonic development whereas its abnormal activity 
has been associated to cancer development (Chanoumidou et al., 2017). 
The present study aimed to investigate the role of SOX2 on RasV12-mediated 
transformation in order to better understand whether SOX2 increase the oncogenic effect of 
RasV12 and if this factor influence the response of tumor cells to chemotherapy. Thus, our 
specifics objectives were: 
 
a) To study the mechanisms by which RasV12 induces SOX2 in vitro.  
• Factors involved in induction of SOX2 by RasV12 through several immortalized 
and primary mouse embryonic fibroblasts cell lines knockdown and knockout 
for p53, p19ARF, and Rb genes.  
• Signalling Ras pathway involved in induction of SOX2 mediated by RasV12 
through overactivation and pharmacological inhibition of Ras pathways in vitro. 
 
b) To assess the importance of SOX2 in the oncogenic transformation mediated by Ras V12 
in immortalized and primary mouse embryonic fibroblasts cell lines in vitro through 
transformation assays. 
 
c) To study the effect of SOX2 overexpression in human lung carcinoma and human breast 
adenocarcinoma cell lines on drug therapy in vitro through MTT assays. 
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Materials and Methods 
1. Cell Culture 
1.1 Culture conditions 
The HEK 293T, W3T3, D3T3, WT MEFs, p53-/- MEFs, ARF-/- MEFs, C39 Tag, A549, and MCF7 
parental cell lines (Table 2) were used in this study. Cells were cultured at 370C in a humidified 
5% CO2 incubator and maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, 
D5671) supplemented with 10% fetal bovine serum (FBS) (Gibco Life Technologies, 10270), 1% 
glutamine (Gibco Life Technologies, 25030-024), and 1% penicillin/streptomycin (Gibco Life 
Technologies, 15140-122) for a confluence of 70 to 80%. Re-plating of cells was accomplished 
by using trypsin followed by resuspension cells into fresh medium. 
Cells infected with vector carrying resistance to puromycin, hygromycin, and G418 were 
maintained with 2.25µg/ml of puromycin (Sigma, P8833), 250µg/mL of hygromycin B 
(Invitrogen, 10687-010), and 600 µg/ml of G418 (HyClone, SV30069), respectively. The W3T3 
shNTG and W3T3 shp53 cells were maintained in culture with 3µg/mL of puromycin (Sigma, 
P8833). The A549 EOS GFP Puro, A549 SOX2, MCF7 EOS GFP Puro, and MCF7 Puro cells were 
maintained with 1µg/mL of puromycin, and the A549 Puro and MCF7 SOX2 cells were selected 
with 4µg/mL and 200ng/mL of puromycin, respectively. 
For cryopreservation, cell pellet was dissolved in 1mL DMEM with 10% of DMSO 
(dimethylsulfoxide) (Sigma, D2650), a cryoprotectant that prevents the ice crystals formation. 
 
Table 2. List of parental cell lines. 
Cell line Origin of cell line 
HEK 293T Human embryonic kidney cells transformed 
with large T antigen 
W3T3 Mouse immortalized fibroblasts cells by 3T3 
protocol 
D3T3 Mouse immortalized from Rb-/- embryonic 
fibroblasts 
WT MEFs  Primary mouse embryonic fibroblasts  
p53-/-MEFs  Mouse embryonic fibroblasts p53-/- 
ARF-/-MEFs  Mouse embryonic fibroblasts ARF-/- 
C39 TAg Mouse embryonic fibroblasts immortalized 
by SV40 TAg 
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A549  Human lung carcinoma cells obtained from 
Manuel Collado’s group, IDIS 
MCF7  Human breast adenocarcinoma cells 
obtained from Manuel Collado’s group, IDIS 
 
 
 
1.2 Toxicity curve for antibiotics 
1.2.1 Hygromycin B toxicity curve for W3T3 cells 
Hygromycin B is an aminoglycoside antibiotic produced by Streptomyces hygroscopicus it 
kills prokaryotic and eukaryotic cells by inhibition of translocation of mRNA and tRNA on the 
ribosome (Borovinskaya et al., 2008). This antibiotic was used for selection of W3T3 cells 
transfected with pWZL Hygro and pWZL Hygro H-RasV12 plasmids (hygromycin plasmid 
resistance). 
The antibiotic concentration in cell culture depends on cell line and we don’t know the toxic 
concentration of hygromycin B for W3T3 cells we tested the toxic concentration of 0 µg/mL, 50 
µg/mL, 100 µg/mL, 250 µg/mL, 500 µg/mL, and 750 µg/mL for this antibiotic in W3T3 cells line. 
For W3T3 cells with puromycin resistance (W3T3 Puro) we tested the concentration of 0 µg/mL, 
50 µg/mL, 100 µg/mL, and 250 µg/mL because we already knew the toxic concentration of 
hygromycin B for W3T3 cells. 
We seeded 1.4x104 W3T3 cells in triplicates in 24 wells culture plates and grown 24 hours 
before added the respective concentration of hygromycin B. This experiment was maintained 
eight days in culture, and changed the culture medium every three days. 
The optimal antibiotic concentration that kills the control cells in a week after added 
hygromycin B is 250µg/mL (Figure 7).   
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Figure 7. Optimal concentration of hygromycin B for (A) W3T3 cells and (B) W3T3 cells with puromycin 
resistance. The graphs represent the percentage of dead cells for eight days of exposition to different 
concentrations of antibiotic hygromycin B. 
 
 
1.2.3 G418 toxicity curve for W3T3 shNTG cells 
The G418 is an aminoglycoside antibiotic, an analogue of neomycin sulphate that interferes 
with the function of 80S ribosomes and protein synthesis in eukaryotic cells. We used this 
antibiotic for selection of W3T3 cells transfected with pInducer RasV12 plasmid. 
The toxic concentration of neomycin for W3T3 shNTG cells was unknown, we tested 
concentrations of 0 µg/mL, 200 µg/mL, 400 µg/mL, 600 µg/mL, and 800 µg/mL. 
We seeded, 1.4x104 W3T3 cells in triplicates in 24 wells culture plates and growth 24 hours 
before added the respective concentration of G418. This experiment was maintained eight days 
in culture, and changed the culture medium every three days.  
The optimal antibiotic concentration that kill the control cells in a week after added is 
600µg/mL (Figure 8). 
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Figure 8. Optimal concentration of G418 for W3T3 pInducer H-RasV12 cells. The graph represents the 
percentage of dead cells for eight days of exposition to different concentrations of antibiotic G418. 
 
 
1.3 Viral infections 
1.3.1 DNA amplification of retroviral and lentiviral plasmids 
In this work, we used  Ψ2helper, pBabe Puro, pMXS-SOX2 IP, pBabe Puro H-RasV12, pWZL 
Hygro, pWZL Hygro H-RasV12, pBabe H-RasV12 C40, pBabe H-RasV12 E38, pBabe H-RasV12 G37, 
pLp1, pLp2, pLp VSVG, and pInducer 20 RasV12 plasmids. To DNA amplifications we prepared 
the plasmids at a concentration of 100-200ng/µl and added 2µl of plasmids to 25µl of DH5α 
competent bacteria, except for lentival plasmid pInducer 20 H-RasV12 that grown in ccdB 
bacteria. Plasmids were incubated with bacteria 20 minutes in ice, 45 seconds to 420C, and two 
minutes in ice again. After, added 1mL of SOC (super optimal broth) medium (Table 3) and 
incubated for 1.5 hours on a shake to 175rpm and 370C. We put 100µl of previous solution in a 
plate of Lysogeny broth (LB) medium + agar with 100µg/mL ampicillin (Sigma, A9518) and 
incubated 12 to 24 hours to 370C. 
Next, we grow the bacteria in small volume of LB medium (Table 3) with the antibiotic, for 
that we put a colony of bacteria in 10mL of LB medium with 100µg/mL of ampicillin and 
incubated for eight hours on a shake to 225rpm and 370C. After, we growth the bacteria in 
250mL of LB medium with 100µg/mL of ampicillin overnight in the same conditions. To increase 
the number of copies of DNA, the bacteria with pInducer 20 H-RasV12 plasmid were incubated 
over 12 hours with 170µg/mL of chloramphenicol in the same conditions. 
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We centrifuged the bacteria in LB medium for 15 minutes to 5000 g at 4oC and to isolate 
the plasmid we used a protocol of NucleoBond® Xtra Midi (Macherey-Nagel, 740410-50). The 
pellet of plasmid was dissolved in TE pH 8.0 (10Mm Tris-Cl pH 8.0 and 1Mm EDTA pH 8.0) and 
store to -200C. 
To store bacteria colony with the plasmid to -800C, we added 300µl of glycerol to 700µl of 
bacteria in LB medium. 
 
Table 3. Composition of SOC and LB medium.  
SOC medium LB medium (1L) 
2% tryptone 
0.5% yeast extract 
10mM NaCl 
2.5mM KCl2 
10mM MgCl2 
10mM MgSO4 
20mM glucose 
 
10g tryptone 
5g yeast extract 
10g NaCl 
H2O 
Adjust the pH 7.5 with NaOH 
 
 
 
 
1.3.3 Transfection using calcium phosphate-DNA precipitate method 
Transfections of the HEK 293T packaging cells, which enables the encapsulation and release 
of viral particles, with the different plasmids (Table 4), was performed by calcium phosphate 
method. For retroviral transfections we used 15µg of a plasmid that encodes the structural 
proteins of the virus (gag and pol) (Ψ2helper) and 15µg of plasmid containing the gene of 
interest. However, for lentiviral transfections we need 7.5 µg of a lentiviral packaging plasmid 
containing the HIV-1 gag and pol genes (pLP1), 7.5 µg of a lentiviral packaging plasmid containing 
the HIV-1 rev gene (pLP2), 7.5 µg of a lentiviral packaging plasmid for expression of the vesicular 
stomatitis virus G glycoprotein (pLP/VSVG), and 7.5 µg of a lentiviral plasmid containing the gene 
of interest, in this case pInducer 20 H-RasV12 plasmid (Table 5).  
Briefly, 3x106 HEK 293T cells were plated in 100mm culture plates and incubated for 24 
hours. Three hours before the transfection, the culture medium was replaced to 9mL, the cells 
must be, approximately, with 70% of confluence. In a Falcon tube, we added 500µl of 2x HeBS 
(1.5 mM Na2HPO4.7H2O, 274 mM NaCl, 54.5 mM HEPES) and in an eppendorf tube prepared the 
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mixture: 50µl of 2.5M CaCl2, 30µg of DNA, and H2O up to 500µl per culture plate. While bubbling 
the 2x HEBS was added the mix of CaCl2 and DNA and let sit the mixture 20 minutes at room 
temperature to allow the formation of calcium phosphate crystals. The solution was placed in 
each HEK 293T culture plates and 18 hours after incubation changed the medium (washed two 
times with PBS) to avoid toxic effects on cells. We collected the supernatants of the packaging 
cells 48 hours after the last medium replaced, centrifuged five minutes to 500 rpm, and filter 
through a 0.45µm filter. The viral supernatants were frozen at -800C until used in infections. 
 
Table 4. Plasmids used in experiments and its function. 
Plasmids Function 
pBabe Puro Retroviral plasmid control with puromycin 
resistance 
pMXS-SOX2 IP Retroviral plasmid for SOX2 overexpression 
and puromycin resistance 
pBabe Puro H-RasV12  Retroviral plasmid for overexpression of 
active form of H-Ras and puromycin 
resistance 
pWZL Hygro Retroviral plasmid control with hygromycin 
resistance 
pWZL Hygro H-RasV12 Retroviral plasmid for overexpression of 
active form of H-Ras and puromycin 
resistance 
pBabe H-RasV12 C40 Retroviral plasmid for overactivation of PI3K 
pathway and puromycin resistance 
pBabe H-RasV12 E38 Retroviral plasmid for overactivation of 
MAPK pathway and puromycin resistance 
pBabe H-RasV12 G37 Retroviral plasmid for overactivation of 
RalGDS pathway and puromycin resistance 
pInducer 20 H-RasV12 Lentiviral plasmid for inducible expression of 
H-RasV12 (Tet-ON) and neomycin resistance 
pMIG Retroviral plasmid with GFP expression  
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Table 5. Amounts of DNA used in transfection with retroviral plasmids and lentiviral plasmids. 
Transfection with retroviral plasmids Transfection with lentiviral plasmids 
15µg of 𝚿𝟐 helper plasmid - encodes the 
structural proteins of the virus (gag and pol) 
15µg plasmid containing the gene of interest 
7.5µg pLP1 - lentiviral packaging plasmid 
containing the HIV-1 gag and pol genes 
7.5µg pLP2 - lentiviral packaging plasmid 
containing the HIV-1 rev gene 
7.5µg pLP/VSVG - lentiviral packaging plasmid 
for expression of the vesicular stomatitis 
virus G glycoprotein 
7.5µg plasmid containing the gene of interest 
 
  
 
 
 
1.3.4 Viral transduction  
1.3.4.1 Infection with viral supernatants 
Infections with retroviral supernatants were used to produce different cell lines, through 
the infection of W3T3, D3T3, WT MEFs, p53-/- MEFs, ARF-/- MEFs, and C39 TAg parental lines with 
plasmids mentioned in the table 4. We also infected W3T3 shNTG and W3T3 shp53, which were 
previously generated in the laboratory with pWZL Hygro and pWZL Hygro H-RasV12. 
We plated 12 500 cells/cm2 (50-60% of confluence) and incubated for 24 hours. To increase 
the success rate of this process, we did two rounds of the infection. The viral supernatants were 
thawed to 370C and target cells were incubated with 4mL of viral supernatants with 4µg/mL of 
polybrene (Sigma, H9268) for four hours. The process was repeated one more time and added 
double volume of fresh medium (8mL) to each plate. After 24 hours since the beginning of viral 
infection, the medium was replaced and 48 hours after infection started the selection of 
transformed cells or cells were collected for protein extraction and RNA extraction. Cells were 
selected with 2.25µg/mL of puromycin for cells infected with plasmid pBabe Puro, pBabe Puro 
H-RasV12, pBabe Puro H-RasV12 C40, pBabe Puro H-RasV12 E38, and pBabe Puro H-RasV12 G37, 
250µg/mL of hygromycin B for cells infected with pWZL Hygro and pWZL Hygro H-RasV12, and 
600µg/mL of G418 for cells infected with pInducer 20 H-RasV12 plasmid. Clones were selected 
until death of cells control. 
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To originate W3T3 (W3T3 Puro-Hygro), W3T3 Ras (W3T3 Puro-Ras), W3T3 SOX2 (W3T3 
SOX2 IP-Hygro), W3T3 SOX2-Ras (W3T3 SOX2 IP-Ras), W3T3 and p53-/- MEFs shEV, W3T3 and 
p53-/- MEFs shEV Ras, W3T3 and p53-/- MEFs shSOX2, and W3T3 and p53-/- MEFs shSOX2 Ras, the 
retroviral transductions were divided in two phases. In the first phase W3T3 cells were infected 
with viral supernatants of Puro and SOX2 IP, and W3T3 and p53-/- MEFs cells were infected with 
viral supernatants of shEV (short hairpin control RNA) and shSOX2 (short hairpin SOX2 RNA) 
from Miguel Fidalgo’s group, CiMUS. In the second phase cells obtained from the first infections 
were infected with viral supernatants of Hygro and Hygro-Ras. 
Briefly, 12 500 cells/cm2 (50-60% of confluence) W3T3 cells were plated in 100 mm plate 
culture and were incubated for 24 hours. To increase the success rate of the process, we did two 
rounds of the infection. The Puro and SOX2 IP viral supernatants were thawed to 370C and target 
cells were incubated with 4mL of viral supernatant with 4µg/mL of polybrene for four hours. The 
process was repeated one more time and added double volume of fresh medium (8mL) to each 
culture plate. We plated 12 500 cells/cm2 W3T3 and p53-/- MEFs cells (50-60% of confluence) in 
six wells culture plates and incubated for 24 hours. The shEV and shSOX2 viral supernatants were 
thawed to room temperature and target cells were incubated with 0.5mL of culture medium 
and 100µl of viral supernatant with 4µg/mL of polybrene (Sigma, H9268) for four hours, and we 
added 1.5mL culture medium to each well. The medium of infected cells was replaced 24 hours 
after starting the viral infections and 48 hours after infection we started the selection of 
transformed cells with 2.25µg/mL of puromycin for cells transfected and finished when the 
control cells died. 
To the second phase, the cells were seeded at same density in 100mm culture plate and 
incubated for 24 hours with respective antibiotic. The viral supernatants were thawed to 370C 
and target cells were incubated with 4mL of viral supernatant with 4µg/mL of polybrene for four 
hours. The process was repeated one more time and added double volume of fresh medium 
(8mL) to each culture plate. After 24 hours since the beginning of viral infection, the medium 
replaced and 48 hours after infection the cells were selected with 2.25µg/mL of puromycin and 
250µg/mL of hygromycin B until the death of the control cells.  
The confirmation of the infections was made through western blotting assays to confirm 
the expression of SOX2 and Ras proteins as mentioned in the point 2. 
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1.4 Cellular response to treatment with doxorubicin  
Doxorubicin is a chemotherapeutic agent capable of induce apoptosis by activated the ROS 
(oxygen-reactive species) and the p53 protein pathway that promote the transcription of p21 
protein. In these assays, we intend observe the expression of p53 and p21 through western 
blotting in samples treated with doxorubicin to check that this pathway still active. 
We seeded 8x105 cells per 100mm culture plate of each cell line and grown for 24 hours. 
Cells were treated with 0.5µg/mL of doxorubicin in DMSO and cells control were treated with 
same volume of DMSO for 16 hours, depending on the cell line. Following, we proceed to cellular 
lysis and confirmation of protein expression by western blotting as mentioned in the point 2.  
 
 
1.5 Viability assay 
The MTT assay is used to estimate the cell viability, once the viable cells with active 
metabolism covert MTT (thiazolyl blue tetrazolium bromide) into formazan product, its quantity 
can be measured by recording changes in absorbance at 570nm using a plate reading 
spectrophotometer. The formazan accumulates as an insoluble precipitate inside cells as being 
deposited near the cell surface and in culture medium, and must be solubilized prior with 
solubilization solution. When cells die lose the ability to convert MTT into formazan, MTT signal 
is relates with cell number. 
For these experiments, we seeded 4x103 of A549 EOS GFP, A549 EOS GFP Puromycin, A549 
Puro, A549 SOX2, MCF7 EOS GFP, MCF7 EOS GFP Puromycin, MCF7 Puro, and MCF7 SOX2 cells 
in 96 wells culture plates and were incubated for 24 hours. The A549 and MCF7 were treated 
with 0, 0.5, 1, 2.5, 5, 10, 25, and 50µM of doxorubicin, the A549 cells were also treated with 0, 
2.5, 5, 10, 25, 50, and 100 nM of docetaxel, and the MCF7 cells were treated with 0, 25, 50, 100, 
200, 400, and 800 nM of docetaxel and 0, 25, 50, 100, 200, 500, and 1000 nM of gemcitabine for 
48 hours. We added 10µl of MTT solution (5mg/mL) (Alfa Aesa, L11939) per well and incubated 
for four hours, and added 100µl of solubilization solution (1mL of 1M HCl and 10g of SDS) per 
well and incubated overnight. The quantity of formazan was measured by recoding changes in 
absorbance at 570nm. 
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2. Assessment of protein expression by western blotting  
2.1 Protein extraction and quantification 
For protein extractions we plated 8x105 cells in 100mm culture plates and incubated for 24 
hours or we collected the cells 48h after viral infection. In ice, we washed the cells two times 
with PBS 40C and added to the culture plates or cellular pellets (after centrifugation at 1000g for 
five minutes between washes) 70µl of lysis buffer (Table 6). After, we collected the cells for 
eppendorf tube, incubated on ice for 20 minutes, and lysis the cells by sonication in three pulses 
of five seconds with 30% amplitude (keeping the samples in ice to prevent protein degradation). 
Following centrifuged the samples at 16 000g for 15 minutes at 40C, the protein supernatant 
was collected and kept at -800C for later use. 
We used the Bradford method to protein quantification. We prepared six BSA standard 
(1µg/µL) with the concentrations 0, 1, 2, 4, 8, and 10µg/µl and the samples of cell lines. To each 
sample and standard, we added 1mL of Coomassie (Bradford) protein assay reagent (Thermo 
Fisher Scientific, 1856209) and the colorimetric reaction could develop for 10 minutes at room 
temperature. The absorbance (595nm) was measured in a spectrophotometer (Thermo 
Spectronic, BioMate3), where that standard 0µg/µl was used as blank for the standards lecture 
and lysis buffer used as blank for the samples. 
 
Table 6. Composition of RIPA and lysis buffers. 
RIPA buffer Lysis buffer 
5M NaCl 
1M Tris-HCl pH 7.5 
0.1% SDS 
1% Triton X-100 
1M EDTA pH 8.0 
0.5% Sodium deoxycholate 
H2O 
1mM Na3VO4 (sodium orthovanadate) 
1M PMSF 
1M DTT  
4mM NaF 
 1x cocktail of proteinases inhibitors (Thermo 
Scientific, 1862209) 
RIPA  
 
  
 
 
2.2 Western blotting 
The samples, equal amount, were mixed with a Laemmli charge buffer, a denaturing buffer 
(50% glycerol, 10% SDS, 5% β-mercaptoethanol, 0.5% bromophenol blue, 0.4M Tris pH 6.8), and 
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were incubated five minutes to 950C. Thus, we eliminate the protein three-dimensional 
structure, so proteins are separated on the gel based on their molecular weight. 
Proteins from the cell extracts were separated by vertical electrophoresis (25mA and 200V) 
in denaturing gel of acrylamide: bis-acrylamide of size 8.5x6.5cm with 5% stacking gel and 12% 
or 15% resolving gel. Two distinct phases divide these two gels: the upper phase (stacking gel) 
in which the proteins homogenize and the lower phase (resolving gel) that allows the protein 
separation by molecular weight. The percentage of acrylamide in the resolving gel depends on 
protein under study. 
 
Table 7. Composition of solution for prepare stracking and resolving gels. 
 Stracking gel Resolving gel 
5% (4mL) 12% (7mL) 15% (7mL) 
30% acrylamide mix 670µl 2.8mL 3.5mL 
1.5M Tris pH 8.8 500µl 1.75mL 1.75mL 
10% SDS 40µl 70µl 70µl 
10% ammonium 
persulfate 
40µl 70µl 70µl 
TEMED (Sigma, 
T9281) 
4µl 2.8µl 3µl 
H2O 2.7mL 2.3mL 1.61mL 
 
 
After the electrophoresis, proteins present in the gel were transferred to 45 µm Hybond-
PVDF membrane (Merch Millipore, IPVH 00010). The membrane was placed 30 seconds into 
methanol and submerged in water for least five minutes to activate the membrane, this process 
is to membrane pass hydrophobic to hydrophilic for that the protein binding to membrane for 
hydrophobic bond and charge, lastly membrane was transferred to transfer buffer B for least 
five minutes. We placed six sheets of Whatman in transfer buffer A and C and three sheets of 
Whatman in transfer buffer B and stack sheets of transfer buffer A, gel, membrane PVDF 
(polyvinylidene difluoride), and sheets of transfer buffer B and C (Table 8). The stack was 
positioned onto semi-dry blotter (Sigma) with that gel facing to the positive pole and the 
membrane for negative pole, once the protein transfer is made from the positive pole for 
negative pole. Transfers were performed by a current of 0.8mA/cm2 on the membrane for 1.5 
hours. 
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Table 8. Solutions for semi-dry transference. 
Transfer Buffer A (1L) Transfer Buffer B (1L) Transfer Buffer C (1L) 
100mL 0.4M e-aminoceproic 
acid and 0.25M Tris base 
20mL 1.25M tris base 200mL 1.25M tris base 
200mL of isopropanol 200mL of isopropanol 200mL of isopropanol 
700mL of H2O 800mL of H2O 600mL of H2O 
 
 
Membranes were incubated, in constant agitation, for least two hours at room temperature 
in blocking solution (0.05% TNT solution containing 5% milk powder) to block nonspecific 
protein. 
After blocking, membranes were washed, to remove excess buffer, three times for 10 
minutes in 0.05% TNT solution. Membranes were incubated with a primary antibody overnight 
at 40C in constant agitation under the following conditions (Table 9).  
 
Table 9. Solutions for membrane washing and antibody incubation (TNT) and antibodies used in 
membrane hybridization.  
TNT 0.05% (500mL) 0.5% (500mL) 1% (500mL) 
1M Tris HCl pH 7.5  12.5mL 12.5mL 12.5mL 
5M NaCl 15mL 15mL 15mL 
Tween® 20 (Fisher 
BioReagents, BP337) 
0.25mL 2.5mL 5mL 
H2O 472.25mL 470mL 467.5mL 
 
Antibody Applier references  Dilution Incubation solution 
SOX2 Santa Cruz Biotechnology 
(Y-17), sc-17320 
1:500 1% TNT 
pan-Ras Oncogene (Ab-3), cat#OP40 1:200 1% TNT 
 
α-p53 
Cell signalling (1C12)  
 
Santa Cruz Biotechnology 
(A-1), sc-393031 
 
1:1250 
 
1:1000 
 
1% TNT 
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α-p21 Santa Cruz Biotechnology 
(F-5), sc-6246 
1:200 1% TNT 
p19ARF Santa Cruz Biotechnology 
(5-C3-1), sc-32748 
1:500 1% TNT 
Phospho-p44/42 
MAPK (P-ERK1/2)  
Cell signalling (197G2), 
cat#4377 
1:1000 0.1% TNT + 5% BSA 
(Sigma, A2153) 
p44/42 MAPK 
(ERK1/2) 
Cell signalling, cat#9102 1:1000 0.1% TNT + 5% BSA 
(Sigma, A2153) 
α-Tubulin Sigma (DM1A), cat#T9026 1:3000 1% TNT  
α-GAPDH Millipore (6C5), 
cat#MAB374 
1:7500 1% TNT 
α-Goat IgG HRP Santa Cruz Biotechnology, 
sc-2020 
1:5000 0.5% TNT 
α-Mouse IgG HRP GE Healthcare, NA931V 1:5000 0.5% TNT 
α-Rabbit IgG HRP GE Healthcare, NA934V 1:5000 0.5% TNT 
α-Rat IgG HRP Vector, cat#PI9401 1:1000 0.5% TNT 
 
 
After the incubation, membranes were washed three times for 10 minutes with 1% TNT 
solution. To allow the detection of antigen-antibody interaction, the membranes were 
incubated with second antibody associated with HRP (Horse-Raddish Peroxidase) diluted in 0.5% 
TNT solution for 45 minutes at room temperature. Membranes were washed again three times 
for 10 minutes in 0.5% TNT solution.  
To detect the proteins, membranes were incubated with ECL western blotting substrate 1:1 
(Thermo Scientific, 32106) for one minute to room temperature in the dark. The binding of the 
substrate to peroxidase associated with the antibody (HRP) produces a light reaction that allows 
its detection by autoradiography. The medical x-ray films were exposed until it was possible to 
visualize the proteins of interest. 
To observe the expression of different proteins in same membrane can be used the 
stripping and reprobing western blots method, which involves the extraction of membrane-
bound antibodies, followed by incubation with the desired antibody.  To remove the antibodies, 
the membrane was incubated at 500C for 30 minutes in stripping buffer (62.5mM Tris pH 6.8; 
2% SDS; 100mM ß-mercaptoethanol). 
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3. Cell transformation assay: foci formation assay 
The cell foci formation assay allows to test if cells maintain proliferation inhibition by cell-
cell contact or they lost this feature. The loss of the competent inhibition by cell-cell contact is 
a hallmark of cancer cells. In this assay, we mixed the cells to test with W3T3 parental line which 
maintained contact inhibition, and observed if the interest cell line grows or not over the 
parental line.  
For these experiments we seeded 4x105 W3T3 cells (wild-type) with 400 of interesting cell 
line in six wells culture plates and were incubated for 11 days. The culture medium was replaced 
every three days.  
Cells were washed two times with PBS 40C, fixed and stained with a staining solution (4% 
formaldehyde to 37%, 4% glacial acetic acid, 60% methanol, 1% crystal violet) for 30 minutes to 
room temperature and finally, all excess dye was removed using water. The plates were left to 
dry for a few hours and the cellular foci counted.  
 
 
4. Inhibition of Ras pathways 
4.1 RasV12 expression with an inducible system   
In these experiments, we used W3T3 cells infected with a Ras Tet-ON plasmid (pInducer 20 
H-RasV12) as mentioned in 1.3.4 point. The tetracycline-controlled transcriptional activation is 
a method of inducible gene expression where transcription is reversibly turned on or off in the 
presence of the antibiotic tetracycline or doxycycline, a more stable tetracycline derivative. This 
plasmid has a Tet response element (TRE) that is seven repeats of 19 nucleotide tetracycline 
operator sequence. In the absence of doxycycline, the gene expression, in this case H-RasV12, is 
inhibited. In presence of this antibiotic, doxycycline binds to reverse tetracycline-controlled 
transactivator (rtTA) that binds to TRE and subsequent activated the gene expression.  
We must first know if the RasV12 expression is activated in the presence of doxycycline and 
the time in which we observed increased SOX2 expression after activating the RasV12 expression 
with doxycycline.  For the first point, we seeded 8x105 cells in 100mm culture plates and grow 
for 24 hours. The cells were treated with 6µg/mL of doxycycline (Sigma, D9891) in PBS while the 
control cells were treated with same volume of PBS for 24 hours. Following, proceed to cellular 
lysis and confirmation of Ras protein expression by western blotting as mentioned in the point 
2. 
For time course experiments, we seeded 3x105 cells in six wells culture plates, incubated 24 
hours, and treated 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours with doxycycline. Then, the cells were 
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collected to RNA extraction and reverse transcription (RT) quantitative PCR analysis, as 
mentioned in the point 5. 
 
 
4.2 Treatment of cells with Ras pathways inhibitors 
To determine the Ras pathway essential for the induction of SOX2 transcription factor by 
RasV12, we begin by confirming that the inhibitors block the respective Ras pathway. We seeded 
8x105 W3T3 pInducer H-RasV12 cells in 100mm culture plates and grow for 24 hours in 10% 
serum. The medium was replaced by serum deprivation medium (0.2% serum) and the cells were 
treated with 6µg/mL of doxycycline for six hours and with the respective Ras pathway inhibitor, 
10µM PD98059 (Calbiochem, 513000) for six hours, 15µM SB202190 (Calbiochem, 559388) for 
one hour, 20µM LY294002 for five hours, 2.5µM MK-22062 for four hours, and 1µM GDC-0068 
(Ipatasertib) for two hours in DMSO. The controls of these experiments were cells in serum 
deprivation for six hours, cells in 10% serum for six hours, cells in serum deprivation with 
doxycycline for six hours, and cells in serum deprivation with doxycycline and DMSO for six 
hours. The cells were treated in independent culture plate for each Ras pathway inhibitors and 
controls. Following, proceed to cellular lysis and detection of Ras, p-ERK, and total ERK protein 
expression by western blotting as mentioned in the point 2. 
The next step was to study the mRNA SOX2 expression in the presence of Ras pathway 
inhibitors, PI3K/PDK1/AKT and MAPK.  For this, we seeded 3x105 W3T3 pInducer H-RasV12 cells 
in six wells culture plates and grow for 24 hours in 10% serum. In the next day, the cells in serum 
deprivation (0.2% serum) were treated with 6µg/mL of doxycycline for six hours and with the 
respective Ras pathway inhibitor, 10µM PD98059 for six hours, 20µM LY294002 for five hours, 
2.5µM MK-22062 for four hours, and 1µM GDC-0068 for two hours in DMSO. As controls we 
used, cells in serum deprivation and cells in serum deprivation with doxycycline and DMSO for 
six hours. The cells were treated in independent culture plate for each Ras pathway inhibitors 
and controls (Figure 9). Then, the cells were collected to RNA extraction and RT quantitative PCR 
analysis, as mentioned in the point 5.  
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Figure 9. (A) Inhibitors of the Ras pathways used in W3T3 pInducer RasV12 cells. (B) Experimental 
timeline for treatment of W3T3 pInducer RasV12 cells with MAPK and PI3K/AKT pathways inhibitors. 
Cells were treated with 6µg/mL of doxycycline in serum deprivation (0.2% serum) for six hours and each 
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culture plate/well were treated with different Ras inhibitors at different times and concentration in the 
presence of doxycycline  
 
5. Gene expression study by RT-quantitative PCR  
 5.1 RNA extraction  
To extract RNA from different cell lines, we seeded 12500 cells/cm2 and infected with pBabe 
Puro and pBabe Puro Ras, as referred to in 1.3.4 point. The cells were washed two times with 
PBS at 4oC, 48 hours after the infection, and collected the cells with lysis buffer and β-
mercaptoethanol (Sigma, M3148), as referred in the RNA extraction kit. Cells were stored at 
-21oC until used.  
We seeded 3x105 cells/21cm2 of pInducer H-RasV12 cell line in a six wells culture plates and 
treated with doxycycline as referred to in point 4. After the treatments, cells were washed two 
times with PBS at 4oC, collected, and stored as referred to above. 
After thawing the samples, the RNA extractions were performed using the GenElute™ 
Mammalian Total RNA Miniprep Kit (Sigma, RTN70) and NucleoSpin® RNA (Macherey-Nagel, 
740955) for W3T3 pInducer H-RasV12 cell line. RNA was stored at -80oC until used to cDNA 
synthesis. 
 
 
 5.2 cDNA synthesis for reverse transcription (RT) 
In reverse transcription, double-stranded DNA is synthesized from a RNA strand by a 
reverse transcriptase enzyme.  
For this reaction is necessary a reverse transcriptase (M-MLV RT), dNTPs (to add during the 
synthesis), random primers (points that serve as a template to initiate the synthesis), and RNase 
Out (recombinant ribonuclease inhibitor). This method allows to determine, in a relative way, 
the amount of mRNA expressed in a cell line or tissue. For each sample in study, the greatest 
amount of cDNA obtained is co-related with highest degree of expression of a particular gene.  
The protocol of retrotranscription is based on a series of incubations. We incubated five 
minutes at 65oC the mixture of 1µg of sample (RNA), 250ng of random primers (Invitrogen, P/N 
58875), and 1.5µl of dNTPs mix (10mM of dATP, dGTP, dCTP e dTTP) (Invitrogen) with a final 
volume of 19µl. To the last mixture were added 6µl of first strand buffer 5x (Invitrogen, 
1820972), 3µl of 0.1M DTT (Invitrogen, P/N y00147), and 1µl of RNase Out™ (Invitrogen, P/N 
100000840), and incubated two minutes at 37oC. Finally, was added 1µl of M-MLV RT 
Role of SOX2 on RasV12-mediated transformation 
 
64 
 
(Invitrogen, 28025-013) and incubated at 25oC for 10 minutes and 50 minutes at 50oC. The 
reaction ended when the solution was incubated at 70oC for 15 minutes and cDNA is ready to 
use in the quantitative PCR. 
  
 
 5.3 Quantitative PCR  
The quantitative PCR allows simultaneous, amplification, and detection of the expression 
of a gene of interest. This method is based on the use of a cDNA fragment (TaqMan probe) to 
an intermediate part of the DNA in the sample. This probe carries attached fluorophore in the 
5’ end and a quencher (fluorescence inhibitory molecule) in the 3’ end.  
While the primer remains free the fluorescence emitted by the fluorophore is corrected by 
the inhibitor. However, when the primers bind to the cDNA of the sample the activity of 
polymerase responsible for the sequence elongation causes the hydrolysis of the inhibitor 
(quencher). So, the energy emitted by the fluorophore will be detected by a sensor. The amount 
of fluorescence emitted during each cycle of the PCR will be proportional to the amount of 
amplified DNA.  
These probes used in quantitative PCR assays are designed in such way that the possibility 
of exogenous DNA amplification is minimal. Thus, for each sample we added a retrotranscription 
control which didn’t include the M-MLV RT enzyme.  
During the assays, for the SOX2 gene, the expression levels of two housekeeping genes 
were measured, to ensure that the amount of the initial cDNA is equivalent for each sample. 
Furthermore, the measure of each gene in each sample performed in duplicate or triplicate. 
In these experiments, for each sample (1.5µl cDNA + 7.5µl H2O) we added 1µl of 20x 
TaqMan (Table 10) and 10µl of 2x Master Mix (Applied Biosystems, 94404). The cDNA was 
amplified (40 cycles) in quantitative PCR instrument (Life technology-applied Biosystems) under 
the following conditions: 10 minutes at 95oC, 15 seconds at 95oC, one minute at 60oC, and to 4oC 
indefinitely.  
 
Table 10. List of the genes and their TaqMan probes used for RT quantitative PCR analysis. 
Gene Probe reference 
SOX2 Mm03053810_s1 
GUSB Mm01197698_m1 
TFRC Mm00441941_m1 
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6. Statistical analysis 
Graphical analysis was performed in Microsoft Excel 2010 software and results were 
statistically analyzed by T-student test in which the values with p˂0.05 (* p <0.05; ** p <0.01; 
*** p <0.001) were considered statistically significant and the graph represent the mean ± SD 
(standard deviation). 
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Results 
 
RasV12 overexpression induces SOX2 expression 
SOX2 has an important role in several biological processes, such as maintenance of 
pluripotency and stemness (Arnold et al., 2011). In cancer cells, this factor is involved in survival 
and proliferation both in vivo and in vitro studies (Ren et al., 2016). 
In this project, we used H-RasV12 as an oncogenic model in vitro. To determine the effect 
of SOX2 overexpression in cancer cells we developed cell lines that overexpressed RasV12 (W3T3 
Ras), SOX2 (W3T3 SOX2), SOX2 and RasV12 (W3T3 SOX2-Ras), and cell line control (W3T3) by 
retroviral infection. The advantage of retroviral infections is that each cell contains only one 
copy of plasmid, so the gene expression isn’t related to the number of copies of the plasmid in 
the cell. 
 We observed the increased of SOX2 expression in W3T3 SOX2 cells and expression of SOX2 
and Ras in W3T3 SOX2-Ras cells. Cells that overexpressed RasV12 (W3T3 Ras) present the levels 
of Ras increased as well as SOX2 (Figure 10). The cell lines are morphological different from each 
other, and the cells that overexpressed RasV12 are morphological more elongated than cells 
expressing basal levels of this oncogene (Figure 11). 
 
 
 
 
 
 
 
 
 
Figure 10. The expression of SOX2 protein increases in cells expressing RasV12. The amounts of SOX2 
and Ras were determinate by western blotting in W3T3 cells infected with the Ras and SOX2 plasmids 
after cell selection (A representative result of two independent experiments is shown).  
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Figure 11. The (A) W3T3, (B) Ras, (C) SOX2, and (D) SOX2-Ras cell lines are morphological different. 
Representative picture of these cells 24 hours after seeded at the density of 13 560 cells/cm2.  
 
 
SOX2 cooperates with RasV12 in cell transformation 
In normal cells, the cell-cell contact work as an inhibitor of cell proliferation forming 
monolayer of confluent cells (2D culture). Several types of cancer cells lose the ability to inhibit 
the proliferation through cell-cell contact (Hanahan and Weinberg, 2011). As already described, 
cells expressing oncogenic RasV12 lose this ability and form cell foci (Jacobsen et al., 2002).  
To determine the effect of SOX2 overexpression in the transformation mediated by RasV12, 
we plated a foci assay where we use W3T3, to form the monolayer of confluent cells, with the 
W3T3, W3T3 Ras, W3T3 SOX2, and W3T3 SOX2-Ras cell lines to observe they capacity to form 
cell foci.  
Both the cell lines with RasV12 overexpression, W3T3 Ras and W3T3 SOX2-Ras, formed cell 
foci and the control cells (W3T3) and cells with SOX2 overexpression (W3T3-SOX2) didn’t lose 
the ability to inhibit the proliferation through cell-cell contact since they weren’t able to form 
cell foci. In cells with SOX2 and RasV12 overexpression (W3T3 SOX2-Ras) the number of foci 
increased when compared to cells that only overexpressed RasV12 (174.1±4.4 in SOX2 and Ras 
cells versus Ras cells values of 113.8±4.3), although the cell foci are smaller in size in cells that 
overexpressed SOX2 and RasV12 (Figure 12). Thus, our results demonstrate that SOX2 increase 
the effect of RasV12 in cell transformation.  
A B 
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Figure 12. The transcription factor SOX2 cooperates with RasV12 in cell transformation. (A) Foci 
formation by crystal violet staining of W3T3 cells infected with SOX2 and RasV12 plasmids, selected, and 
400 of these cells were plated with 4x105 W3T3 cells and grown 11 days prior to staining and counting of 
foci. (B) Graphic showing the number of cell foci for each cell line, data are shown as mean ± SD of the 
number of cell foci (***p˂0.001). This experiment was repeated thrice for each clone (A representative 
result of three independent experiments is shown). 
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Expression of SOX2 is downregulated by culture time 
During the culture time, we observed changes in cell behaviour after about 10 cell passages. 
When we analyze that SOX2 and Ras expression in the W3T3, W3T3 Ras, W3T3 SOX2, and W3T3 
SOX2-Ras we detected the loss of SOX2 expression in W3T3 Ras and W3T3 SOX2 cells (Figure 
13). Thus, SOX2 levels decreased during the time culture, approximately 25 days after infection 
with RasV12 or SOX2 plasmids. So, during the time culture we lose the cells with high levels of 
SOX2. 
 
 
Figure 13. The expression of transcription factor SOX2 is lost approximately 25 days in culture.  The 
expression of SOX2 and Ras were determinate by western blotting of cells collected (*) 15 days and (+) 30 
days after the infection (A representative result of two independent experiments is shown).  
 
 
Acute induction of SOX2 by RasV12 expression 
As present in previous results, during the time culture the cells infected with RasV12 loss 
SOX2 expression. To prevent this loss, we wanted to study SOX2 effects short time after RasV12 
expression. So, we tested the degree of infection with a pMIG plasmid (that expresses GFP) and 
the expression of SOX2 48 hours after the infection.   
To analyze the degree of infection, we infected the W3T3 cells with pMIG plasmid and 48 
hours after infection observed the amount of EGFP expression in microscopy. We observed that 
about 90% of the cells are infected with the plasmid (Figure 14A). Using a western blotting 
method, we detected the increase of SOX2 expression in W3T3 cells 48 hours after the infection 
with RasV12, without selection (Figure 14B). Thus, we could do the experiments 48 hours after 
the infection without selection because we have a high degree of infection and can detect SOX2 
expression. 
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Figure 14. SOX2 induction can be detected 48 hours after infection in W3T3 cells. (A) The W3T3 cells 
were infected with pMIG plasmid and observed the amount of EGFP expression in microscopy 48 hours 
after the infection. (B) The W3T3 cells were infected with H-RasV12 plasmid, collected 48 hours after the 
infection, and the expression of SOX2 and Ras were determinate by western blotting.  
 
 
Genetic requirements for RasV12-mediated SOX2 induction  
Mouse embryonic fibroblasts (MEFs) are a classic model system for studying cell 
senescence and immortalization. Cells that sustain spontaneous damage in p53/p19ARF pathway 
(p14 in humans) can overcome this replication block, leading to gradual outgrowth of an 
immortalized cell population with unlimited growth potential (Odell et al., 2010). 
In immortalized MEFs, mutations in p53 and p19ARF silencing by biallelic deletion are the 
two most common routes to spontaneous p53/p19ARF pathway inactivation. The p16/Rb 
pathway, a senescence master regulator, is also commonly affected during the immortalization. 
These genetic alterations are also common in human tumors (Odell et al., 2010). 
Prevalence of cell lines immortalized by p19ARF biallelic deletion or p53 mutations was not 
unexpected because most 50% of cell lines depending on immortalization protocol, but the 
surprised is that a significant fraction of cell lines appeared to have retained WT p53 and p19ARF 
expression (Odell et al., 2010).  
The tumor suppressor p53 has an important role in cell cycle, apoptosis, and senescence, 
inducing factors such as p21 following DNA damage and p16 as a result of premature senescence 
(Yu et al., 2012; Charni et al., 2016).  
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Since the immortalization event in W3T3 cells is unknown, we analyze if these cells 
maintained an active p53 pathway or if these results are due to p53 inactivation. For that, we 
treated the cells with 0.5µg/mL doxorubicin for 16 hours and analyze the expression of p53 and 
p21 proteins. Doxorubicin is a chemotherapeutic agent, which can induce apoptosis by the 
activation of p53 pathway.  
Although we didn’t observe an increase in p53 protein levels in cells treated with 
doxorubicin, p21 expression was increased. W3T3 Ras cells seem to have higher basal levels of 
p21 (something that doesn’t happen with the other cell lines; Figure 15). This demonstrates that 
the p53 pathway remains active in W3T3 cells because we could detect the expression of p21 
protein upon p53 inactivation. Thus, p53 inactivation is not the immortalization event in W3T3 
cells since these cells behave as p53 positive.  
 
 
 
 
 
 
 
 
 
 
Figure 15. W3T3 cells infected with SOX2 and H-RasV12 plasmids maintain functionally active p53.  The 
cells were plated 8x105 cells/100mm dish, grown for 24 hours, and treated with 0.5µg/mL of doxorubicin 
for 16 hours. The expression of p53 and p21 were determinate by western blotting (A representative 
result of two independent experiments is shown). 
 
The p53 tumor suppressor is activate and promote the cellular senescence and apoptosis 
in response to cellular stress, such as the overexpression of Ras (Ramadoss et al., 2016). To 
determine if p53 is a key factor in increase of SOX2 expression via RasV12, once p53 is functional 
in W3T3 cells as present in previous results, we infected W3T3 p53 knockdown cells with RasV12 
and detect the expression of SOX2 48 hours after infection. We also observed the expression of 
SOX2 in W3T3 Rb knockout cells (D3T3), where we aren’t able to detect the SOX2 expression. 
We study the expression of other factors as p53 and p19ARF, we observed that p53 expression is 
increased in W3T3 Ras cells and in D3T3 cells the expression of this protein stabilized. The 
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expression of p19ARF was increased in W3T3 Ras and D3T3 Ras cells (Figure 16). The p53 factor 
isn’t required for SOX2 induction in W3T3 cells upon RasV12 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Expression of SOX2 increases upon RasV12 expression in W3T3, W3T3 shNTG, and W3T3-
shp53 cell lines, but not in D3T3 cells. The W3T3, D3T3, W3T3 shNTG, and W3T3 shp53 cells were infected 
with H-RasV12 plasmid and collected 48 hours after the infection. The amounts of SOX2, Ras, p53, and 
p19ARF were assessed by western blotting (A representative result of two independent experiments is 
shown). 
 
As p53 is stabilized in D3T3 control and Ras cells (figure 15), we wanted to test if p53 
remained functional in these cells. Thus, cells were treated with 0.5µg/mL doxorubicin for 16 
hours and p53 and p21 expression was measured by western blotting.  
We didn’t observe the expression of p21 in D3T3 cells treated with doxorubicin, suggesting 
that p53 is inactive in these cells. So, D3T3 cells are functionally Rb and p53 knockout (Figure 
17). 
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Figure 17. D3T3 cells don’t have active the p53 pathway. The cells were plated 8x105 cells/100mm dish, 
grown for 24 hours, and treated with 0.5µg/mL of doxorubicin for 16 hours. The expression of p53 and 
p21 were determinate by western blotting (A representative result of two independent experiments is 
shown). 
 
To confirm if the D3T3 cells infected with RasV12 induce SOX2 or not, we selected the cells 
infected and detected SOX2 expression by western blotting method. After selection, we 
observed the induction of SOX2 expression by RasV12 in D3T3 cells (Figure 18). Thus, Rb is not 
required for SOX2 induction by RasV12 expression, although Rb deficiency could delay the 
induction of SOX2. 
 
 
 
 
 
 
 
 
 
Figure 18. RasV12-mediated SOX2 induction in D3T3 cells. The D3T3 cells were infected with H-RasV12 
plasmid, selected, and the amounts of SOX2 and Ras determinate by western blotting (A representative 
result of two independent experiments is shown). 
 
As we don’t know the immortalization event of W3T3 cells and, to rule out the influence of 
other genetic effects, we switch to a genetically defined system as primary mouse embryo 
fibroblasts (MEFs). We infected WT MEFs, p53-/- MEFs, ARF-/- MEFs, and C39 TAg with RasV12 
and detected the expression of SOX2, Ras, p53, and p19ARF 48 hours after the infection. We 
observed the increase of SOX2 expression in all cell lines that expressed RasV12, except in the 
ARF-/- MEFs cells where we weren’t able to detect the expression of SOX2. In the C39 TAg cells 
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the increased of SOX2 expression it’s not so obvious because the high basal level of SOX2 
expression in these cells. The overexpression of RasV12 leads to the increased of SOX2 
expression in cells knockout for p53 and Rb, but not in p19ARF knockout cells. Thus, these results 
confirmed that p53 and Rb are not required for SOX2 induction upon RasV12 expression, but 
p19ARF could be required in the induction of SOX2. 
We can’t observe the expression of p53 in WT MEFs and ARF-/- MEFs Ras cells and in C39 
TAg cells, TAg inactivates and stabilizes p53. The p19ARF expression is increased in WT MEFs and 
p53-/- MEFs cells upon RasV12 expression since p19ARF is induced in the presence of oncogenic 
RasV12 (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. RasV12 mediated SOX2 induction in WT MEFs, p53-/- MEFs, and C39 TAg cell lines, but not in 
ARF-/- MEFs cell line. The MEFs, p53-/- MEFs, ARF -/-MEFs, and C39 TAg cells were infected with H-RasV12 
plasmid and collected 48 hours after the infection. The amounts of SOX2, Ras, p53, and p19ARF were 
determinate by western blotting (A representative result of two independent experiments is shown). 
 
SOX2 is induced by oncogenic RasV12 in W3T3, D3T3, W3T3 shNTG, W3T3 shp53, WT MEFs, 
p53-/- MEFs, and C39 TAg cells. 
We wanted to confirm if p53 is functional in these cells because we can’t observe the 
expression of p53 in WT MEFs and ARF-/- MEFs Ras cells, as shown in figure 18. The cells are 
treated with 0.5µg/mL doxorubicin for 16 hours and detected the p53 and p21 expression by 
western blotting.  
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In cells WT MEFs and ARF-/- MEFs cells treated with doxorubicin we detected p21 
expression, as well as p53 expression in the last cell line. Thus, the WT MEFs and ARF-/- MEFs 
cells have the p53 pathway functional (Figure 20).  
 
 
 
 
 
 
 
 
Figure 20. WT MEFs and ARF-/- MEFs have an active p53 pathway. The cells were plated 8x105 
cells/100mm dish, grown for 24 hours, and treated with 0.5µg/mL of doxorubicin for 16 hours. The 
expression of p53 and p21 were determinate by western blotting (A representative result of two 
independent experiments is shown). 
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RasV12 induces SOX2 expression at transcriptional level  
As observed in previous results RasV12 induced the expression of SOX2 and to determine 
if this induction is at the level of transcription, we analyze the amount of SOX2 mRNA in cells 
that overexpressed RasV12. The WT MEFs and ARF-/- MEFs cells were infected with RasV12 and 
48 hours after the cells are collected and SOX2 mRNA analysis by RT quantitative PCR. 
The SOX2 mRNA mediated by RasV12 is higher in WT MEFs cells than in ARF-/- MEFs cells 
(5.1±0.75 versus WT MEFs Ras values of 40.7±32). Cells with overexpression of RasV12 have 
increased levels of SOX2 mRNA, so the oncogenic RasV12 induce the transcription of SOX2 gene 
(Figure 21).  
 
 
  
 
 
 
 
 
 
 
 
Figure 21. The transcription factor SOX2 is induced by oncogenic RasV12 at the level of transcription. 
The (A) WT MEFs and (B) ARF-/- MEFs cells were infected with H-RasV12 plasmid and collected the RNA 48 
hours after the infection. The level of SOX2 mRNA was analyzed by RT quantitative PCR (A representative 
result of three independent experiments is shown). Graphic showing the mean ± SD of amount of SOX2 
mRNA for each cell line (*p˂0.05, **p˂0.01). 
 
In previous results we observed through protein expression that in MEFs cells KO for ARF 
(ARF-/-MEFs) the oncogenic RasV12 couldn’t induce the expression of SOX2 transcription factor 
48 hours after the infection with H-RasV12, as we observed in other cell lines (Figure 19). 
However, through RT quantitative PCR we observed the induction of SOX2 mRNA mediated by 
RasV12 in the same cells 48 hours after the infection with H-RasV12 plasmid (Figure 21B). 
We couldn’t detect the protein expression of SOX2 in ARF-/- MEFs cells probably because 
SOX2 undergoes some post-translational modification, for example SUMOylation. 
We conclude that RasV12 induced the expression of SOX2 in ARF-/- MEFs cells, so p19ARF 
isn’t an essential factor for the induction of SOX2 thought the Ras pathway. 
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Signalling pathways downstream of Ras that mediate SOX2 induction 
Activation of Ras is one of the most common molecular events in human cancer since Ras 
protein interacts directly with numerous effector proteins, which then induce cellular responses. 
Mutations in codon 12 of Ras, for example V12, prevent GTP hydrolysis resulting in a 
constitutively active form of Ras protein (McFarlin et al., 2003). 
The activated form of Ras (H-RasV12) induced the expression of the transcription factor 
SOX2, as shown the previous results, but we don’t know which pathway downstream of Ras is 
responsible for the induction of SOX2. To determine which Ras signalling pathway is involved in 
SOX2 induction, we selectively activated different Ras pathways using RasV12 mutants for each 
pathway or, alternatively inhibited the PI3K/AKT and MAPK pathways involved in survival and 
proliferation using pharmacological inhibitors. 
To activate the different Ras pathways, we used three mutants of H-RasV12 C40, E38, and 
G37. The mutant C40 (H-RasV12C40) have a mutation from tyrosine to cysteine in codon 40 that 
retains the affinity with PI3K, effector protein of Ras, but greatly reduces the affinity with RalGDS 
and Raf. Mutations from aspartic acid to glutamic acid in codon 38 (H-RasV12E38) maintain the 
affinity with Raf, but lacks affinity with RalGDS and PI3K. The mutant H-RasV12G37 have a 
mutation from glutamic acid to glycine in codon 37 that reduces the affinity with Raf and PI3K, 
but retains the affinity with RalGDS (McFarlin et al., 2003). 
We infected the W3T3 cells with pBabe Puro, pBabe Puro H-RasV12, and the three H-
RasV12 mutants, C40, E38, and G37. The cells were selected until death of cells control and 
observed the expression of SOX2 and Ras in the different mutants by western blotting. Only the 
infection with the RasV12E38 mutant was able to cause a significant increase in the expression 
of Ras protein, while in the C40 and G37 mutants we don’t detect the expression of Ras. 
However, when the MAPK pathway is activated by E38 mutant we didn´t observe the increase 
of SOX2 expression as when all Ras pathways are activated (W3T3 Ras cells). We analyzed also 
ERK expression to prove if the MAPK pathway is, effectively, activated. We detected the 
expression of ERK in H-RasV12E38 mutant, so this mutant activated the MAPK pathway, but the 
activation of this cascade isn’t sufficient to induce SOX2 expression as occurs in cells that have 
all Ras pathways activated. We failed to detect the other RasV12 mutants, so we cannot 
conclude if these are sufficient or not to induce SOX2 (Figure 22).  
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Figure 22. The overactivation of MAPK pathway by H-RasV12E38 mutant isn’t enough for induction of 
SOX2 expression by RasV12. The W3T3 cells were infected with H-RasV12 and three different H-RasV12 
mutants (C40, E38, and G37) and selected. The expression of SOX2, Ras, phospho-ERK, and total ERK was 
observed by western blotting (A representative result of three independent experiments is shown). 
 
We next tested which pathway could be required for SOX2 induction through the inhibition 
of two main Ras pathways, the PI3K/AKT and MAPK cascades. We started by confirming if the 
W3T3 pInducer H-RasV12 cells induced the expression of Ras in the presence of doxycycline and 
determining the shortest time in which we could observe the increase in SOX2 mRNA expression. 
The W3T3 cells were infected with pInducer H-RasV12 plasmid, selected, treated with 6µg/µl 
doxycycline for 24 hours, and observed the expression of Ras by western blotting. We observed 
the increased of Ras expression in these cells 24 hours after added doxycycline, so we could use 
this model for the next steps (Figure 23A).  
To determine the shortest time in which it is observed the induction of SOX2 mRNA 
expression mediated by RasV12, we treated the W3T3 pInducer H-RasV12 with doxycycline 
during 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours and analysis the amount of SOX2 mRNA by RT 
quantitative PCR. We observed the induction of SOX2 mRNA expression six hours (2.4 for six 
hours versus 1.2 for 0 hours) after the activation of RasV12 expression using doxycycline (Figure 
23B).  
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Figure 23. (A) Doxycycline induced the Ras protein expression in W3T3 pInducer H-RasV12 cells. Cells 
were treated with 6µg/µl doxycycline for 24 hours and detected Ras expression by western blotting. (B) 
RasV12 induced the SOX2 mRNA expression six hours after the activation of RasV12 with doxycycline 
in W3T3 pInducer H-RasV12 cells. Cells were treated with 6µg/µl doxycycline for 0, 1, 2, 3, 4, 6, 8, 12, and 
24 hours and the SOX2 mRNA expression analyzed by RT quantitative PCR. Graphic shows the amount of 
SOX2 mRNA for different times with doxycycline. 
  
To confirm if all inhibitors prevent the activation of the respective Ras pathway, we treated 
the W3T3 pInducer H-RasV12 cells in serum deprivation with 10µM PD98059 for six hours, 15µM 
SB202190 for one hour, 20µM LY294002 for five hours, 2.5µM MK-22062 for four hours, and 
1µM GDC-0068 for two hours and analyzed the expression of Ras, phospho-ERK, and total ERK 
by western blotting. We observed that in presence of 6µg/µl doxycycline for six hours the 
expression of RasV12 is activated, the MAPK inhibitor PD98059 in these conditions inhibit this 
pathway because we detect the decrease of phospho-ERK expression, but the SB202190 don’t 
inhibit this pathway in under these conditions (Figure 24A). 
To analyze the amount of SOX2 mRNA in the presence of Ras inhibitors to know, which is 
the Ras pathway, PI3K/AKT and MAPK, essential for the induction of SOX2 mediated by RasV12, 
we treated the W3T3 pInducer H-RasV12 cells in serum deprivation and in presence of 6µg/µl 
doxycycline with 10µM PD98059 for six hours, 20µM LY294002 for five hours, 2.5µM MK-22062 
for four hours, and 1µM GDC-0068 for two hours. After six hours with doxycycline and the time 
with the respective treatment, we procedure to the RNA extraction and analyzes the amount of 
SOX2 mRNA by RT quantitative PCR. We observed that when we inhibited the MAPK pathway 
by PD98059, RasV12 loses the ability to induce the expression of SOX2 (0.53±0.1 versus DMSO 
control values of 1±0). For the PI3K/AKT inhibitors the values of SOX2 mRNA induction by RasV12 
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are 1.04±0.36, 1.23±0.22, and 1.27±0.32 for LY294002, MK-22062, and GDC-0068 inhibitors, 
respectively. This shows that activation of the MAPK pathway is necessary for SOX2 induction 
mediated by RasV12. We cannot conclude if it’s the only essential pathway in the induction of 
SOX2 expression by RasV12, because we need to confirm if the PI3K/AKT pathway is inhibited 
with any inhibitor used (Figure 24B). 
 
 
Figure 24. The MAPK pathway is necessary for SOX2 induction mediated by RasV12.  The W3T3 pInducer 
H-RasV12 cells were treated in serum deprivation in the presence of 6µg/µl doxycycline with 10µM 
PD98059 for six hours, 15µM SB202190 for one hour, 20µM LY294002 for five hours, 2.5µM MK-22062 
 -     +     -     -     -     -     -     -     - Serum 
  -     -     +     +    +    +    +    +    + Doxycycline 
W3T3 pInducer RasV12 
D
M
SO
 
P
D
9
8
0
5
9
 
SB
2
0
2
1
9
0
 
LY
2
9
4
0
0
2
 
M
K
-2
2
0
6
2
 
G
D
C
-0
0
6
8
 
Ras 
p-ERK 
ERK 
GAPDH 
A 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
M
ea
n
±S
D
 o
f 
SO
X
2
 m
R
N
A
    -           -           -          -           -           -    Serum 
    -           +          +          +          +           +    
Doxyxycline 
** 
B 
21 KDa 
42, 44 KDa 
42, 44 KDa 
37 KDa 
Role of SOX2 on RasV12-mediated transformation 
 
81 
 
for four hours, and 1µM GDC-0068 for two hours. (A) The expression of Ras, p-ERK, and total ERK proteins 
were analyzed by western blotting. (B) The amount of SOX2 mRNA was analyzed by RT quantitative PCR 
(A representative result of three independent experiments is shown). Graphic showing the mean ± SD of 
amount of SOX2 mRNA for controls and the different treatments (**p˂0.01). 
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SOX2 mediates transformation by RasV12 
Previous results showed that the overexpression of SOX2 increase the oncogenic 
transformation of RasV12 and that RasV12 induces the expression of SOX2. 
To determine if SOX2 is an important factor for the oncogenic transformation, we silenced 
the SOX2 gene using a shRNA in immortalized W3T3 and in p53-/- MEFs cells. Next, we infected 
the shRNA cells with H-RasV12, selected the cells, and seeded for a cell foci assay. We checked 
the effect of the SOX2 knockdown by western blotting 48 hours after the infection with H-
RasV12. 
We observed that RasV12 was able to induce SOX2 in W3T3 and p53-/- MEFs cells when a 
control shRNA was used. The shSOX2#1 was not able to prevent SOX2 induction in W3T3. 
Interestingly, the cells infected with the second shRNA against SOX2 (shSOX2 #2) was able to 
prevent increase of SOX2 expression upon RasV12, as we intended (Figure 25).  
 
 
Figure 25. Efficient knockdown of SOX2 in W3T3 cells and p53-/- MEFs. (A) The W3T3 cells were infected 
with empty vector (EV) and two vectors of shSOX2 (#1 and #2) and selected. (B) The p53-/- MEFs cells were 
infected with empty vector (EV) and shSOX2 #2 vector and selected. The W3T3 and p53-/- MEFs cells shEV 
and shSOX2 were infected with RasV12 and 48 hours after the infection collected some cells to analyze 
the SOX2 and Ras protein expression by western blotting (A representative result of three independent 
experiments is shown for W3T3 cells and a representative result of two independent experiments is 
shown for p53-/- MEFs cells).  
 
We plated cell foci assays with the control cells (shNTG), and cells with SOX2 down 
regulated (shSOX2) after the cell selection. We observed that W3T3 shSOX2 RasV12 form fewer 
cell foci that the control cells (W3T3 shNTG) which express SOX2 (43.8±4.5 for W3T3 shSOX2#2 
Ras and 37.1±13.3 for W3T3 shSOX2#1+#2 Ras versus W3T3 shNTG Ras values of 243.0±23.6). 
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cells (p53-/- MEFs shNTG) (58.2±9.8 for p53-/- MEFs shSOX2 Ras versus p53-/- MEFs shNTG Ras 
values of 83.7±9.0) (Figure 26). 
Since, SOX2 knockdown in RasV12 cells leave to formation of fewer foci cell, so RasV12 can’t 
increase the SOX2 expression and its oncogenic transformation capacity decreases. 
Figure 26. The transcription factor SOX2 is important for cell transformation mediated by oncogenic 
RasV12. (A) Foci formation by crystal violet staining of W3T3 and p53-/- MEFs cells infected with shSOX2 
and H-RasV12 plasmids, selected, and 400 of these cells were plated with 4x105 W3T3 cells and grown 11 
days prior to staining and counting of foci. Graphics showing the number of cell foci for each (B) W3T3 
and (C) p53-/- MEFs cell lines and, data are shown as mean ± SD of the number of cell foci (***p˂0.001). 
This experiment was repeated thrice for each clone (A representative result of three independent 
0
10
20
30
40
50
60
70
80
90
100
M
ea
n
±S
D
 o
f 
n
u
m
b
er
 o
f 
ce
ll 
fo
ci
Cell line
*** 
Hygro 
RasV12 
W3T3 
shSOX2 
#1 + #2 
W3T3 
shSOX2 
#2 
W3T3 
shEV 
p53-/- 
MEFs 
shSOX2 #2 
p53-/-
MEFs 
shEV 
A 
B C 
0
50
100
150
200
250
300
M
ea
n
±S
D
 o
f 
n
u
m
b
er
 o
f 
ce
ll 
fo
ci
Cell line
***  
***  
Role of SOX2 on RasV12-mediated transformation 
 
84 
 
experiments is shown for W3T3 cells and a representative result of two independent experiments is 
shown for p53-/- MEFs cells). 
 
 
SOX2 overexpression increases the resistance of cancer cells to drug 
therapy  
SOX2 not only influences tumor growth, but it also influences the response of tumor cells 
to drugs used clinically (Wuebben et al., 2016). The development of resistance to therapy is a 
clinical problem in several cancers, such as breast and lung cancer (Chou et al., 2013; Piva et al., 
2014), and the endocrine treatment failure and poor relapse-free survival is correlated with 
higher levels of SOX2 (Piva et al., 2014).  
To study if SOX2 overexpression could cause the development of resistance to drugs used 
in chemotherapy, we used two tumor cell lines transfected with SOX2 to induce overexpression. 
We treated control and SOX2 human lung carcinoma (A549) cells with doxorubicin and 
docetaxel, and human breast adenocarcinoma (MCF7) cells with doxorubicin, docetaxel, and 
gemcitabine for 48 hours and analyzed the cell viability by MTT assay. 
Before starting the treatments, we confirmed the SOX2 expression in these cells by western 
blotting, and we observed that the A549 and MCF7 cells infected with pMx-SOX2-IP vector 
expressed higher SOX2 levels when compared to control cells (Figure 27). 
 
 
Figure 27. Increased expression of SOX2 in (A) A549 SOX2 and (B) MCF7 SOX2 cell lines. The A549 and 
MCF7 cells were infected with EOS GFP, EOS GFP Puromycin, pBabe Puro, and pMx SOX2 IP vectors from 
Manuel Collado’s group, IDIS. The expression of SOX2 protein were determinate by western blotting. 
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Our treatment results show that in human lung carcinoma (A549) cells the overexpression 
of SOX2 factor doesn’t increase the resistance of these cells to doxorubicin (Figure 28) and 
docetaxel (Figure 29), when we compared with the control cells with basal levels of SOX2. 
However, SOX2 overexpression also doesn’t make the A549 cells more sensitive to the 
treatment. In human breast adenocarcinoma cells (MCF7) the overexpression of SOX2 factor 
didn’t make the cells more resistant or sensitives to doxorubicin (Figure 30) and gemcitabine 
(Figure 31) drugs. However, MCF7 SOX2 cells treated with docetaxel are more resistance to the 
therapy in the concentration of 25, 50, 100, and 400nM (0.319±0.03, 0.287±0.04, 0.138±0.02, 
and 0.189±0.02 for MCF7 SOX2 versus MCF7 Puro values of 0.142±0.03, 0.168±0.02, 0.027±0.03, 
and 0.088±0.02, respectively) (Figure 32).  
SOX2 overexpression makes the human breast adenocarcinoma cells more resistances to 
docetaxel drug, a paclitaxel derivative used in chemotherapy. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. SOX2 overexpression doesn’t increase the resistance of A549 cells to doxorubicin. Cells were 
treated with 0, 0.5, 1, 2.5, 5, 10, 25, and 50µM of doxorubicin for 48 hours and the cell viability measure 
by MTT assay. The graphics represents the cell viability for the different concentration. Data are shown as 
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mean ± SD of cell viability. This experiment was repeated thrice for each concentration (A representative 
result of two independent experiments is shown). 
 
 
 
 
Figure 29. SOX2 overexpression doesn’t increase the resistance of A549 cells to docetaxel. Cells were 
treated with 0, 2.5, 5, 10, 25, 50, and 100 nM of docetaxel for 48 hours and the cell viability measure by 
MTT assay. The graphics represents the cell viability for the different concentration. Data are shown as 
mean ± SD of cell viability. This experiment was repeated thrice for each concentration (A representative 
result of two independent experiments is shown). 
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Figure 30. SOX2 overexpression doesn’t increase the resistance of MCF7 cells to doxorubicin. Cells were 
treated with 0, 0.5, 1, 2.5, 5, 10, 25, and 50 µM of doxorubicin for 48 hours and the cell viability measure 
by MTT assay. The graphics represents the cell viability for the different concentration. Data are shown as 
mean ± SD of cell viability. This experiment was repeated thrice for each concentration (A representative 
result of four independent experiments is shown). 
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Figure 31. SOX2 overexpression doesn’t increase the resistance of MCF7 cells to gemcitabine. Cells were 
treated with 0, 25, 50, 100, 200, 500, and 1000 nM of gemcitabine for 48 hours and the cell viability 
measure by MTT assay. The graphics represents the cell viability for the different concentration. Data are 
shown as mean ± SD of cell viability. This experiment was repeated thrice for each concentration (A 
representative result of four independent experiments is shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. SOX2 overexpression increases the resistance of MCF7 cells to docetaxel. Cells were treated 
with 0, 25, 50, 100, 200, 400, and 800 nM of docetaxel for 48 hours and the cell viability measure by MTT 
assay. The graphics represents the cell viability for the different concentration. Data are shown as mean 
± SD of cell viability (*p˂0.05; ***p˂0.001). This experiment was repeated thrice for each concentration 
(A representative result of five independent experiments is shown). 
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Discussion 
 
The transcription factor SOX2 is essential for maintaining the pluripotency and self-renewal 
of embryonic stem cells and play an important role in the reprogramming of differentiated 
somatic cells into pluripotent stem cells (Bareiss et al., 2013).  
Life is not possible without SOX2 expression, in particular during the embryogenesis, but 
this factor also has a dark side when we talk about tumorigenesis. In the last years, SOX2 
expression has been detected in several tumors, including ovary, lung, skin, brain, breast, and 
prostate, suggesting that SOX2 also regulates tumorigenesis. SOX2 is a cancer stem cell marker 
and can induce stem cells properties such as stemness, tumor-initiating capacity, and apoptosis 
resistance and is also implicated in growth, drug resistance, metastasis, and poor survival. 
However, only recently the study of the effects of this factor on tumorigenicity, prognosis, and 
drug resistance in human cancer has begun (Bareiss et al., 2013; Wuebben and Rizzino, 2017).  
On the other hand, the implication of Ras proteins in pathological processes, including 
cancer and physiological processes controlling cellular proliferation, differentiation, and survival 
has been extensively studied since its discovery 30 years ago.  Mutations in ras gene are frequent 
in some of the cancers with the worst prognoses (Fernández-Medarde and Santos, 2011). The 
Ras activity can lead to senescence, cell death, or in the absence of tumor suppressors, to 
transformation. This oncogene can be capable of cellular transformation without oncogenic 
mutation (Logsdon and Lu, 2016). 
SOX2 adopts specific roles in individual tumor types because showing divergent expression 
patterns and function across tumors (Bareiss et al., 2013). Its expression is altered between 
normal and tumorous tissues, so is important understanding the molecular changes necessary 
for tumor initiation and progression. Targeting SOX2 expression or its mode of action could be 
the next step to improve the survival of patients with some of the difficult to treat cancers, but 
for this is necessary understand mechanistically how SOX2 contributes for the biology of the 
tumor (Wuebben and Rizzino, 2017). 
Despite knowing that SOX2 and Ras are expressed in several types of cancer, the role of 
SOX2 in oncogenic transformation mediated by Ras isn’t much studied. Boumahdi and 
colleagues refer that SOX2 is essential for growth and maintenance in vivo in benign and 
malignant skin squamous cell carcinoma and has a key role in the tumour initiation. This factor 
regulates directly and/or indirectly the expression of genes involved in cell proliferation, 
stemness, chromatin remodelling, and metabolism in primary K-Ras (G12D)- induced skin 
tumours in vivo (Boumahdi et al., 2014). In other hand, Xu and collaborators discuss that in lung 
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adenocarcinoma the SOX2 overexpression cause Notch inhibition, a direct target of SOX2 
transcription factor, and suppresses K-Ras-induced tumors. Thus, SOX2 regulates Notch 
transcription and the signalling of Notch is important for K-Ras-induced lung adenocarcinoma 
(Xu et al., 2014).  
In the present work, we used different cell lines of immortalized mouse fibroblasts and 
primary mouse embryonic fibroblasts that overexpressed RasV12 to assess the effect of SOX2 
on RasV12-mediated transformation and the genetic requirements for SOX2 induction mediated 
by RasV12. We also use human lung carcinoma and human breast adenocarcinoma cell lines to 
study the effect of SOX2 overexpression on drug therapy.  
To assess the role of SOX2 in transformation mediated by RasV12 we started by expressing 
RasV12 and/or SOX2 in immortalized mouse fibroblasts (W3T3) and analyze the transformation 
capacity of these cells by transformation assay. We showed that cells infected with H-RasV12 
plasmid overexpressed Ras, cells infected with SOX2 plasmid overexpressed SOX2, and cells 
infected with the two plasmids overexpressed SOX2 and Ras, however we also detected 
overexpression of SOX2 in cells infected with H-RasV12 plasmid. These findings suggest that 
RasV12 induced the expression of SOX2. In the transformation assay with the same cells we 
observed that only the cells that overexpressed Ras could form cell foci, however in cells that 
overexpressed SOX2 and Ras the number of cell foci increased when compared with cells that 
only overexpressed Ras. These results suggest that SOX2 increases the effect of RasV12 in cell 
transformation. Castellano and Downward sugest that cooperation between RalGDS and RAF 
are necessary to induction foci formation in Ras-mediated transformation in vitro (Castellano 
and Downward, 2011). In cell lines derived from many types of cancer the stable overexpression 
of SOX2 is associated with increase tumor cell growth in vitro and in vivo. However, SOX2 
overexpression inhibits tumor cells growth, as was observed in prostate tumor cell line DU145 
and in breast tumor cell lines (Wuebben et al., 2016). The same result was observed by Xu and 
colleagues wherein SOX2 overexpression inhibits K-Ras induced lung adenocarcinoma formation 
and leads to adenoma with squamous features (Xu et al., 2014). 
In cells that overexpressed SOX2 we observed the loss of its expression after 25 days in 
culture. Due to this result we tested the acute induction of SOX2 by RasV12 to avoid loss of data. 
We infected W3T3 cells with H-RasV12 plasmid and analyze the SOX2 expression 48 hours after 
the infection without selection, we observe that RasV12 induce SOX2 in these conditions.  
Gene expression can be regulated by other factors, so to study the genetic requirements 
for Ras-mediated SOX2 induction we started by observed the p53 and p21 expression in W3T3, 
W3T3 Ras, W3T3 SOX2, and W3T3 SOX2-Ras cells because mutation in p53 and p19ARF silencing 
are the two most common immortalization events and we don’t know the immortalized event 
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in this cell line. The cells were treated with doxorubicin and p53 and p21 expression detected by 
western blotting. We observed the increased of p53 expression in W3T3 cells treated with 
doxorubicin and the increased of p21 expression in all the cell lines treated. These findings 
suggest that p53 inactivation isn’t the immortalized event in W3T3 cell line. As p53 is functional 
we studied whether p53 could be a key factor in the induction of SOX2 mediated by RasV12, we 
used W3T3 p53 knockdown (shp53) cells and control cells (W3T3 shNTG) infected with H-RasV12 
plasmid and detected the expression of SOX2 48 hours after the infection. We observed the 
increase of SOX2 expression in W3T3 shp53 cells as well as in control cell line, so p53 wasn’t 
requested for SOX2 induction upon RasV12 expression. We also analyzed SOX2 expression in 
W3T3 Rb knockout cells (D3T3), but we didn’t be able to detect the expression of SOX2 48 hours 
after the infection. However, after cell selection we detect by western blotting, approximately 
five days after the infection, the increased of SOX2 expression in D3T3 cells. This result suggests 
that Rb is not required for SOX2 induction by RasV12 expression, although Rb deficiency could 
delay its induction. We also analyze the expression of p53 and p19ARF in the W3T3, D3T3, W3T3 
shNTG, and W3T3 shp53 infected with H-RasV12 plasmid. We observed the increased of p53 
and p19ARF in W3T3 RasV12 cells and in D3T3 cells the expression of p53 was stabilized, but the 
expression of p19ARF was increased when compared to the control conditions. To study the 
activation of p53 pathway in D3T3 cells we treated the cells with doxorubicin and we didn’t 
observe p21 expression when compared to the control conditions, this suggest that p53 pathway 
isn’t functional in this D3T3 cell line. 
To avoid other genetic effects of W3T3 cells because we don’t know the immortalization 
event we used primary mouse embryonic fibroblasts (MEFs) to continue the study of genetic 
requirements for the induction of SOX2 by RasV12 expression. We infected WT MEFs, p53-/-
MEFs, ARF-/- MEFs, and C39 TAg cell lines with H-RasV12 plasmid and detected the expression of 
SOX2, p53, and p19ARF 48 hours after the infection by western blotting. We showed that RasV12 
induced SOX2 expression in WT MEFs, p53-/- MEFs, and C39 TAg cell lines when compared with 
control cells, although C39 TAg cells have high basal levels of SOX2 as was observed Vilas and 
collaborators that cells lacking Rb or p130 express higher levels of SOX2 (Vilas et al., 2015). In 
ARF-/- MEFs cells upon RasV12 expression we don’t detect the expression of SOX2. Thus, p53 and 
Rb is not required for SOX2 induction mediated by RasV12 and p19ARF could be required for SOX2 
induction. We only detected p53 expression in C39 TAg cells where its expression was stabilized 
because the interaction of T antigen (TAg) with p53 block p53 gene expression and stabilizes p53 
as well as inactivated Rb expression (Pipas, 2009). Nonetheless, we treated WT MEFs, p53-/- 
MEFs, and ARF-/- MEFs with doxorubicin to confirm if p53 pathway is activated by detection of 
p53 and p21 by western blotting. We observed increased of p21 expression in WT MEFs and 
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ARF-/- MEFs cell lines when compared to the control condition, so in these cells p53 pathway was 
activated. The p19ARF expression was increased in WT MEFs and p53-/- MEFs upon RasV12 
expression. Ferbeyre and collaborators refer that oncogenic ras can increase p53 levels and 
leads mouse embryonic fibroblasts cells to a permanent cell cycle arrest with features of cellular 
senescence (Ferbeyre et al., 2002) and in neuronal stem cells (NSCs) the increased levels of SOX2 
leads to accumulation of p53 protein (Marqués-Torrejón et al., 2013). In WT murine 
keratinocytes the overexpression of Ras induces cell cycle, which is mediated by increased 
expression of p19ARF (Meng et al., 2016). 
To assess if the induction of SOX2 by RasV12 is at level of transcription we analyze the 
amount of SOX2 mRNA in WT MEFs and ARF-/- MEFs cells 48 hours after the infection with H-
RasV12 plasmid by RT quantitative PCR. We observed the increase of SOX2 mRNA in both cell 
lines that overexpressed RasV12 when compared to control cell lines. So, RasV12 induce the 
transcription of SOX2 gene. We don’t observe SOX2 expression in ARF-/- MEFs cells by western 
blotting. However, we detect SOX2 mRNA by RT quantitative PCR in the same cells 48 hours of 
the infection with H-RasV12. These findings suggest that p19ARF isn’t an essential factor for SOX2 
induction in cells upon RasV12 expression. We don’t know why we didn’t detect SOX2 protein, 
but probably SOX2 undergoes some post-translational modification, for example SUMOylation. 
We know through previous studies that p19ARF regulates SUMOylation and SOX2 can be modified 
at post-translational level by SUMOylation (Tago et al., 2005; Liu et al., 2013). However, we 
unknown the relationship between p19ARF and SOX2.  
MAPK pathway is essential to control the proliferation, differentiation, and survival of 
eukaryotic cells (Fernández-Medarde and Santos, 2011) and PI3K activation might have an 
important role during tumor maintenance highlights the importance of this pathway as an 
anticancer target (Castellano and Downward, 2011). To study which signalling pathways 
downstream of Ras that mediate SOX2 induction, first we investigated what the Ras pathway is 
responsible to increase the expression of SOX2. We infected W3T3 cells with mutants of the Ras 
pathways PI3K/AKT (C40), MAPK (E38), and RalGDS (G37) and after selection detected SOX2 
expression by western botting. Our results show that only RasV12E38 mutant activated the 
MAPK cascade because we observed the overexpression of Ras and phospho-ERK, but we don’t 
detect the expression of SOX2 when compared with control conditions. However, we failed to 
detect RasV12C40 and G37 mutants because they don’t express Ras. This result suggests that 
RasV12E38 mutant activated the MAPK pathway, but its activation isn’t sufficient to induce SOX2 
expression as occurs in cells that have all Ras pathways activated. McFarlin show in fibroblasts 
that activated Ras have higher transformation efficiency in comparison with RasV12 mutants, 
but Raf of the MAPK pathway appears to be more potent oncogenic effector than PI3K or 
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RalGDS. Raf is the primary oncogenic effector of Ras and its activation can initiate rat mammary 
gland carcinogenesis, while affinity with PI3K or RalGDS is sufficient for carcinogenesis after long 
latency. In vivo the Raf pathway may serve as the single most important pathway to target for 
the prevention and treatment of Ras tumors (McFarlin et al., 2003). 
Next, we tested which pathway could be required for SOX2 induction by inhibiting Ras 
pathways, MAPK and PI3K/AKT, with pharmacological inhibitors. First, we confirmed that 
doxycycline activates Ras expression in W3T3 pInducer RasV12 (Tet-ON) cells and determine the 
shortest time in which observed the induction of SOX2 mRNA expression by RasV12. We also 
confirmed by western blotting that MAPK pathway is inhibited after treated the cells with MAPK 
inhibitor (PD98059) because we observed decreased expression of phospho-ERK when 
compared with the control conditions, but we can’t confirm the inhibition of PI3K/AKT pathway 
in cells treated with PI3K inhibitor (LY294002) and AKT inhibitors (MK-220562 and GDC-0068). 
We analyze the amount of SOX2 mRNA by RT quantitative PCR in cells treated with MAPK and 
PI3K/AKT pathway inhibitors, we observed that RasV12 loses the ability to induce SOX2 
expression when we inhibited the MAPK pathway with PD98059, but RasV12 retains the ability 
to induce SOX2 expression when we inhibit the PI3K/AKT pathway with LY294002, MK-220562, 
and GDC-0068 when compared with the control conditions. These findings suggest that MAPK 
pathway is necessary for SOX2 induction mediated by RasV12, but we don’t know if it’s the only 
essential pathway in the induction of SOX2, because we don’t observe the increase of SOX2 
expression in cells with MAPK pathway active when compared to control conditions. We also 
need to confirm if the PI3K/AKT pathway is inhibited. Hui and collaborators observed in human 
non-muscle-invasive bladder cancer (NMIBC) that the transcription factor SOX2 could be 
regulated by MAPK signalling for maintaining side population or cancer stem cells (CSCs) (Hui et 
al., 2017). Other author refers that RKIP, a Raf kinase inhibitor protein, inhibits SOX2 via its 
inhibition of the MAPK pathway, RKIP is normally bound to Raf-1 and cannot be activated by Ras 
(Lee et al., 2017). These previous results agree with the data observed by us. However, Peltier 
and collaborators refer that in adult hippocampal neural progenitor cells the expression of SOX2 
is regulated by PI3K/AKT signalling pathway, but SOX2 overexpression doesn’t increase cell 
proliferation in contrast with AKT overexpression (Peltier et al., 2011). K-Ras is activated in more 
than 90% of all pancreatic ductal adenocarcinoma (PDAC) and these tumors are highly 
dependent on upregulated AKT and MAPK signalling. Overexpression of SOX2 in PDAC cell lines 
reduced the growth inhibitory effects of trametinib and MK-2206, MEK and AKT inhibitors, 
respectively. Wuebben and colleagues refer when knocking down SOX2 in PDAC cells and 
treated with trametinib or MK-2206 they observed reduction in growth of these cells (Wuebben 
et al., 2016).  
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To assess the importance of SOX2 expression in transformation by RasV12 we used siRNA-
mediated knockdown in W3T3 and MEFs cells and overexpressed RasV12. We confirm the SOX2 
knockdown and Ras overexpression by western blotting and analyze the importance of SOX2 in 
transformation performed a foci assays. In W3T3 and MEFs cells with SOX2 knockdown we 
observed less cell foci, but in MEFs these cell foci are smaller when we compared with the 
control condition, cells that expressed SOX2. These results suggest that the induction of SOX2 
by RasV12 is essential for oncogenic transformation and SOX2 increase the transformation 
capacity of RasV12. Several studies report importance of SOX2 expression in cancer cells growth, 
for example SOX2 promotes esophageal carcinoma growth by regulating the PI3K/AKT signalling 
pathway (Li et al., 2014). In several cancer cell lines, SOX2 knockdown using short hairpin RNA 
(shRNA) decreased tumor cell growth in vitro and/or in vivo, so the expression of SOX2 is 
required to sustain the growth of cancer cells (Boumahdi et al., 2014). Chou and colleagues refer 
that in some lung cancer cells SOX2 knockdown caused significant cell death and attenuated 
tumor growth in xenograft mouse model (Chou et al., 2013). Downregulation of SOX2 expression 
in pancreatic ductal adenocarcinoma (PDAC) cell lines reduced their growth in vitro and in vivo, 
thus SOX2 is required for growth of PDAC (Wuebben et al., 2016). SOX2 is an important 
oncogene in lung and esophageal squamous cell carcinoma and is universally expressed in 
neuroglial tumors and together with other pluripotency genes in glioblastoma. Silencing SOX2 
in glioblastoma affect proliferation and tumorigenicity (He et al., 2011). 
The stem cell signalling is associated with chemoresistance during cancer progression (Chou 
et al., 2013). SOX2 not only influences tumor growth, but it also influences the response of tumor 
cells to therapeutic drugs (Wuebben et al., 2016). We study if SOX2 overexpression influences 
the response of tumor cells to therapeutic drugs. First, we confirmed by western blotting the 
overexpressed of SOX2 in human lung carcinoma (A549) and in human breast adenocarcinoma 
(MCF7) cells and treated A549 cells with doxorubicin and docetaxel and MCF7 cells with 
doxorubicin, docetaxel, and gemcitabine for 48 hours and analyzed the cell viability by MTT 
assays. We observed that the SOX2 overexpression in A549 don´t increase the resistance or 
make this cell line more sensitive to doxorubicin and docetaxel, the same result was observed 
in MCF7 cells treated with doxorubicin and gemcitabine when compared with control 
conditions. However, MCF7 cells that overexpressed SOX2 are more resistance to 25, 50, 100 
and 400 nM of docetaxel therapy. Our results suggest that SOX2 overexpression increase the 
resistance of human breast adenocarcinoma cells to docetaxel. Several studies show that SOX2 
overexpression increased tumorigenicity and chemoresistance, including in gastric and 
colorectal cancer stem-like cells (Li et al., 2014). Tian and collaborators show that in gastric 
cancer cells the overexpression of SOX2 gene increased the insensitivity to the trastuzumab 
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(antibody) administration and patients exhibit a poor clinical response to this treatment (Tian et 
al., 2014). In lung cancer cells (A549), SOX2 expression promoted chemoresistance to cisplatin 
and paclitaxel because this factor increased BCL2L1 expression which protected cancer cells 
from apoptosis and autophagy. The maintenance of mitochondrial integrity and improves cell 
survival by SOX2-BCL2L1 signalling leads to increase chemo-resistant in these cells (Chou et al., 
2013). In breast cancer cells (MCF-7) the ectopic expression of SOX2 is sufficient to make this 
cell line more resistance to tamoxifen treatment in vitro and in vivo (Piva et al., 2014). Ovarian 
cancer cell lines are resistances to carboplatin, cisplatin, and paclitaxel drugs when expressed 
SOX2 and are more sensitive when SOX2 is down regulated (Bareiss et al., 2013). In prostate 
cancer the overexpression of SOX2 is closely correlated with the clinical progress of this cancer 
(Jia et al., 2011) and is responsible for the paclitaxel drug-resistance and the resistance is 
mediated by continuous activation of PI3K/AKT pathway (Li et al., 2014). In head and neck 
squamous cell carcinoma (HNSCC) SOX2 is a mediator of therapy resistance and targeting this 
factor and related molecular downstream pathways may enhance therapy efficacy in this cancer 
(Schröck et al., 2014). Lee and colleagues refer that in cells with SOX2 downregulation the cell 
viability decreases after cisplatin treatment (Lee et al., 2014). In ovarian cancer stem cells, the 
increased of SOX2 expression enables their selective survival to conventional chemotherapies 
and promotes tumorigenicity in vivo. Bareiss and collaborators suggest that SOX2 expression in 
cancer stem cells contribute to therapy resistance and disease relapse in patients with ovarian 
carcinoma. Targeting SOX2 will improve clinical treatment of ovarian carcinoma by enhancing 
apoptosis responses to conventional chemotherapies (Bareiss et al., 2013). As SOX2 increases 
the resistance of the several cancer cells to chemotherapy, this factor may serve as a potential 
therapeutic target for cancer treatment (Chou et al., 2013).  
In conclusion, our results highlight the importance of SOX2 in oncogenic transformation. 
SOX2 expression is induced by RasV12 at level of transcription and SOX2 cooperates with RasV12 
in transformation mediated by this oncogene. We also found that p53, Rb, and p19ARF are not 
essential factors for RasV12-dependent SOX2 induction. Activation of the MAPK pathway is 
required, but not sufficient for SOX2 induction mediated by RasV12 expression. SOX2 expression 
is a clinical problem in the chemotherapy because their overexpression increases the resistance 
to drug therapy decreasing the survival rate of the patient. Ours results show that SOX2 
overexpression increased chemoresistance to docetaxel in breast cell line. In addition, SOX2 is a 
key factor in oncogenic transformation because their inhibition drastically reduces the ability of 
RasV12 to cell foci formation. Based on the above results, SOX2 can be the new therapeutic 
target in the fight against cancer, more precisely in cancer cells with Ras mutations. Future 
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studies, it is still necessary identified the molecular mechanism and partner factors involved in 
the induction of SOX2 by RasV12. 
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Conclusion and Future Perspectives 
 
The transcription factor SOX2 is an important embryonic stem cells regulator and is 
aberrantly expressed in multiple types of human tumours (Sang Hyuk Lee et al., 2014). This has 
an important role in cell cycle regulation, DNA damage repair, and maintaining the totipotency 
of stem cells (Ying et al., 2016). This factor was amplified and overexpressed in many types of 
cancer such as breast, pancreatic, gastric, colon, and lung cancers. The high expression of SOX2 
in many malignant carcinomas is associated with the invasion and poor prognosis of carcinoma, 
this suggest the involvement of SOX2 in carcinogenesis (Liu et al., 2013; Lundberg et al., 2014; 
Ying et al., 2016). 
The present study showed that RasV12 induces SOX2 expression and MAPK pathway is 
required, but not sufficient for SOX2 induction mediated by RasV12 expression. The p53, Rb, and 
p19ARF factors are not essential for SOX2 induction by RasV12. SOX2 expression increases the 
ability of RasV12 in oncogenic transformation, as well as SOX2 overexpression increases 
chemoresistance to docetaxel in breast cell line. 
SOX2 binding loci have been extensively analyzed, but need more investigation to elucidate 
a genome-wide determination of SOX2-interacting partners and a comparative analysis of 
common target gene loci between SOX2 and synergizing factors (Chanoumidou et al., 2017). In 
my opinion, SOX2 can be a novel target for anti-cancer therapy as well as can be used in 
diagnostic, prognostic, and predictive biomarkers. However, know what SOX2 is required in cells 
transformed by RasV12, what is the mechanism by which RasV12 induced SOX2 expression as 
well as factors involved in this process, and the discovery of molecules that can block SOX2 
expression for therapy in tumor cells that have mutations in ras gene may be future lines of 
investigation. 
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